Identification of Novel Therapeutic Approaches and Targets for the Treatment of Ovarian Carcinoma by Stevens, Ellen V.
IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES AND TARGETS FOR 
THE TREATMENT OF OVARIAN CARCINOMA 
 
 
 
 
Ellen Virginia Stevens 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Curriculum in Pharmacology 
 
 
 
 
Chapel Hill 
2010 
 
 
 
 
 
     
    
 
 
 
 
 
 
 
 
 
 
 
          Approved by 
     
                                           Advisors: Channing Der and Lee Graves 
              Reader: Adrienne Cox 
           Reader: Klaus Hahn 
         Reader: Keith Burridge 
    
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2010 
Ellen Virginia Stevens 
ALL RIGHTS RESERVED
 iii 
ABSTRACT 
 
Ellen Virginia Stevens 
Identification of novel therapeutic approaches and targets for the treatment of ovarian 
carcinoma. 
 (Under the direction of Drs. Channing J. Der and Lee M. Graves) 
 
The most imperative issues for ovarian carcinoma patients, due to high relapse rates 
against mainstay therapies, is to identify new molecular targets and develop novel 
therapeutics. This dissertation aims to address both of these issues by 1) defining the 
role, regulation and mechanism of Rho Guanine Nucleotide Dissociation Inhibitor 2 
(RhoGDI2) in ovarian carcinoma and 2) testing nitric oxide (NO)-releasing nanoparticles 
as a potential targeted therapy for ovarian carcinoma. For the first part of my thesis, I 
demonstrated that RhoGDI2 protein expression is elevated in ovarian carcinoma cell 
lines and knockdown of RhoGDI2 in HeyA8 ovarian carcinoma cells results in increased 
Matrigel invasion and tail-vein lung metastasis of HeyA8 cells. RhoGDI2 associates 
primarily with Rac1 in HeyA8 cells and knockdown of RhoGDI2 decreases Rac1 activity 
and translocates Rac1 from the cytosol to membrane protrusions. Mechanistically, the 
phosphorylation of the MKK3/6/p38/JNK components of a key pathway downstream of 
Rac1, which is known to be important for ovarian cancer metastasis, decreased 
following RhoGDI2 knockdown in HeyA8 cells. My results suggest that RhoGDI2 
overexpression contributes to the metastatic phenotype of ovarian carcinoma cells, 
although the exact mechanism responsible remains to be uncovered. For the second 
part of my thesis, I determined anti-tumor efficacy of NO-releasing silica nanoparticles 
against ovarian carcinoma cells. The NO-releasing nanoparticles display enhanced 
growth inhibition against ovarian tumor cells when compared to both control 
 iv 
nanoparticles and a previously developed NO donor drug, PYRRO/NO. Confocal 
msicroscopy analysis revealed that fluorescently-labeled nanoparticles entered the 
cytosol of the cell, released NO, and localized to late endosomes and lysosomes. 
Additionally, we observed that nanoparticle efficacy against normal versus transformed 
ovarian cells depended on their size. Our study demonstrates the first application of 
nanoparticle-derived NO as an antitumor therapy. Collectively, my studies validated 
RhoGDI2 as a metastasis suppressor in ovarian carcinoma and supported the anti-tumor 
efficacy of nanoparticle delivery of NO. 
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CHAPTER 1 
INTRODUCTION 
This work was modified from a published book chapter in Springer  “The Rho GTPases in 
Cancer”, 3-27 (2010). 
 
1.1 Overview of ovarian cancer. Ovarian cancer is one of the most devastating diseases 
for women due to the common delay in diagnosis and poor subsequent treatment success.  
The present mainstays of therapy have an unacceptably high relapse potential and, 
therefore, ovarian cancer patients continue to have a high mortality rate.  There is a general 
consensus among researchers and oncologists that our current “conventional cytotoxic” 
drug approaches have reached their limits of success.  Thus, there remains a high need for 
novel therapeutic approaches for ovarian cancer.  With the recent success in the 
development of molecularly-targeted therapies for cancer (e.g., trastuzumab, imatinib), one 
important new direction will be the identification of novel targets for therapy and 
implementation of those targets for drug design and to develop new drugs for clinical 
application.   
 
The leading cause of death from gynecologic malignancies in the US is epithelial ovarian 
cancer (Jemal et al., 2009). The American Cancer Society estimated that more than 21,000 
women will be diagnosed with ovarian cancer and about 15,000 women will die of the 
disease in 2009. Although many more women will be diagnosed with breast cancer during 
that same time, the mortality rate is around 19%, compared to 56% in ovarian cancer (Jemal 
et al., 2009). This dramatically lower risk of death for women with breast cancer is due, in 
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part, to diagnosis at an early stage either by self examination or by noninvasive breast 
imaging (Huber et al., 2001), and in part, to the development of successful molecularly-
targeted inhibitors of signal transduction (e.g., trastuzumab, aromatase inhibitors). The lack 
of a diagnostic symptom profile or simple noninvasive diagnostic physical examination 
techniques makes ovarian cancer almost impossible to diagnose at an early stage of 
disease. Most women are diagnosed with ovarian cancer after it has spread beyond the 
ovary into the peritoneal cavity. The chance of patients living 5 years after diagnosis in this 
advanced stage is between 20 and 25% (Piver et al., 1990). Ovarian cancer is one of the 
few malignancies in which cytoreductive surgery is performed to remove the bulk of the 
tumor, even where complete resection is impossible (Armstrong et al., 2006). Around 70% of 
ovarian cancer patients will initially respond to a combination of platinum- and taxane-based 
chemotherapy after surgery, with around 50% of the responders eventually relapsing due to 
drug resistant cells that remain dormant for many months and later grow progressively 
(McGuire and Ozols, 1998). Thus, late diagnosis and persistence of dormant, drug-resistant 
cancer cells remains a major limitation in our ability to cure this disease.  
 
Ovarian tumors can be broadly classified into three categories: those derived from the 
surface epithelium, germ cells, and specialized stroma (Goff et al., 2000). Tumors derived 
from the surface of the ovary account for the majority of ovarian tumors (~80%) and are 
referred to as ovarian surface epithelial tumors (Feeley and Wells, 2001). Surface epithelial 
tumors can be further subdivided into benign, borderline (low-malignant potential or atypical 
proliferative) and invasive carcinoma. This type of ovarian cancer is the focus of my 
research studies and will be referred to generally as ovarian cancer in my dissertation. The 
four classes of morphologically-defined epithelial ovarian carcinomas that encompass the 
vast majority of ovarian cancer are serous, endometrioid, clear cell, and mucinous (Goff et 
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al., 2000). Although it is unclear how the epithelial layer gives rise to morphologically distinct 
cancers, it has been suggested that genetic alterations may contribute including oncogenic 
activities in KRAS, BRAF, and AKT, and silencing mutations of TP53, RB, and PTEN 
(Iwabuchi et al., 1995). 
 
The broad goals of my dissertation research were to identify and validate novel targets and 
approaches for ovarian cancer therapy.  My specific aims were to (1) define the role, 
regulation and mechanism of Rho guanine nucleotide dissociation inhibitor 2 (RhoGDI2) in 
ovarian carcinoma growth and 2) assess nitric oxide (NO)-releasing nanoparticles as a 
potential targeted therapy for ovarian carcinoma.  My studies validated RhoGD12 as a 
metastasis suppressor in ovarian cancer and supported the anti-tumor efficacy of 
nanoparticle delivery of NO. 
 
1.2 Rho GTPase history. It is estimated that approximately one percent of the human 
genome encodes proteins that either regulate or are regulated by direct interaction with 
members of the Rho (Ras-homologous) family of small GTPases (Jaffe and Hall, 2005). Rho 
GTPases are low molecular weight proteins (21-28 kDa) that control complex biological 
processes. The most widely studied and best-characterized members are the three 
“classical” members, RhoA, Rac1, and Cdc42, and many of our current concepts of Rho 
GTPase function are based on their properties (Aspenstrom et al., 2007; Wennerberg and 
Der, 2004). They act as binary molecular switches that cycle between two conformational 
states: GDP-bound (‘inactive’ state) and GTP-bound (‘active’ state) and they hydrolyze GTP. 
In the GTP-bound state, Rho is able to activate downstream effectors. There are 20 human 
family members that are regulated by extracellular ligand-stimulated signals initiated from 
upstream cell surface receptors including receptor tyrosine kinases (RTKs), cytokine, 
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adhesion, integrin and G-protein-coupled receptors (GPCRs). They transmit signals to a 
plethora of cytoplasmic effectors that regulate essentially all aspects of normal cell 
physiology (Etienne-Manneville and Hall, 2002).  These include the regulation of cell 
proliferation and survival, cell polarity and morphogenesis, adhesion, migration, growth, 
gene transcription, and vesicular trafficking. Moreover, a causal role for the aberrant 
regulation of Rho GTPases has been found for human disease, including cancer, and in 
neurological and developmental disorders (Govek et al., 2005; Sahai and Marshall, 2002).  
Rho GTPases are also targeted by pathogenic bacteria to facilitate their infection of human 
cells (Finlay, 2005; Munter et al., 2006).  
 
1.3 Evolution of Rho GTPases. The 20 members of the human Rho GTPase family have 
been identified by various approaches (Table 1.1).  The first RHO genes were identified 
serendipitously in 1985 through screening of a sea slug Aplysia cDNA library for the Aplysia 
homolog of human chorionic gonadotropin hormone (Madaule and Axel, 1985) (Figure 1.1). 
At that time in the early 1980s, missense point mutations in the RAS genes (HRAS, KRAS 
and NRAS) had already been discovered in human cancers (Malumbres and Barbacid, 
2003). The mRNA of Rho encodes a 192 amino acid protein that shares 35% sequence 
identity with H-Ras, therefore giving the name Ras-homologous (Rho) (Madaule and Axel, 
1985). Cross hybridization and yeast-two hybrid screens identified three human homologues 
designated RhoA, RhoB and RhoC (Chardin et al., 1988; Yeramian et al., 1987). Also, RHO 
sequences were found to be evolutionarily conserved in the genomes of Drosophila and 
yeast. 
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Table 1.1  Discovery of human Rho GTPases 
Protein Other 
names 
Discovery References 
RhoA ARHA, 
Rho H12 
Identified as a gene related to Aplysia 
Rho in a screen of a human peripheral T 
cell cDNA library.  Aplysia Rho was 
isolated inadvertently in a screen of an 
Aplysia abdominal ganglion cDNA library 
for sequences related to the alpha 
subunit of human chorionic gonadotropin 
hormone, and was found to encode a 
Ras homologous protein. 
(Madaule and Axel, 
1985; Yeramian et al., 
1987) 
RhoB ARHB, 
Rho H6 
Identified as a gene related to Aplysia 
Rho in a screen of a human peripheral T 
cell cDNA library; identified as a gene 
that is rapidly induced in Rat-2 
fibroblasts by transient activation of the 
retroviral tyrosine kinase oncoprotein 
Src. 
(Chardin, 1988; 
Jahner and Hunter, 
1991; Madaule and 
Axel, 1985) 
RhoC ARHC, 
Rho H9 
Identified as a gene related to Aplysia 
Rho in a screen of a human peripheral T 
cell cDNA library; identified as a gene 
overexpressed in breast, melanoma and 
other cancers. 
(Chardin, 1988; Clark 
et al., 2000; Madaule 
and Axel, 1985; van 
Golen et al., 1999) 
Rac1 TC25 Identified as a gene with sequence 
identity to an oligonucleotide encoding 
the peptide sequence FDTAGQEDYD 
from Cdc42/G25K purified from placenta.  
Analyses suggested that it was a Ras-
related C3 botulinum toxin substrate 1, 
although this was later found not to be 
the case; identified using a mixed-
oligonucleotide probe corresponding to 
the conserved DTAGQE GTP binding 
motif of Ras to isolate ras-like coding 
sequences expressed in a human 
NTera2 teratocarcinoma cDNA library. 
(Didsbury et al., 1989; 
Drivas et al., 1990) 
Rac1b Splice 
variant of 
Rac1 
Identified by RT-PCR amplification of 
human Rac1 sequence as a larger 
fragment than expected and found to be 
a splice variant of Rac1 preferentially 
expressed in colorectal and breast 
tumors. 
(Jordan et al., 1999b; 
Schnelzer et al., 2000) 
Rac2  Identified as a gene with sequence 
identity to an oligonucleotide encoding 
the peptide sequence FDTAGQEDYD 
from Cdc42/G25K purified from placenta.  
Analyses suggested that it was a Ras-
(Didsbury et al., 1989) 
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related C3 botulinum toxin substrate 2, 
although this was later found not to be 
the case. 
Rac3  Identified in a search for Rac-related 
sequences by using the murine rac1 
cDNA fragment to screen a human K562 
cell line cDNA library. 
(Haataja et al., 1997) 
RhoG ARHG To isolate coding sequences specifically 
accumulated in late G1, a differential 
screening was performed on a cDNA 
library prepared from CCL39 hamster 
lung fibroblasts stimulated for 5 h with 
serum. 
(Vincent et al., 1992) 
Cdc42p CDC42Hs
, G25K 
Identified as a GTP-binding protein 
expressed in placenta with strong 
sequence identity with the 
Saccharomyces cerevisiae gene product 
discovered as the 42nd mutant involved 
in the morphogenetic events of the cell 
division cycle.  The first Cdc42 gene 
isolated was from S. cerevisiae, and the 
placenta-derived G25K was later 
molecularly cloned. 
(Adams et al., 1990; 
Polakis et al., 1989); 
(Johnson and Pringle, 
1990; Shinjo et al., 
1990) 
Cdc42b G25K; 
splice 
variant of 
Cdc42p 
Identified by screening a human fetal 
braine cDNA library with oligonucleotides 
corresponding to peptide sequences of 
purified G25K, and found to have strong 
sequence identity with Saccharomyces 
cerevisiae CDC42.  This was later shown 
to be a splice variant of the human 
placental Cdc42. 
(Munemitsu et al., 
1990) 
TC10 RhoQ, 
ARHQ, 
RasL7A 
Identified using a mixed-oligonucleotide 
probe corresponding to the conserved 
DTAGQE GTP binding motif of Ras to 
isolate ras-like coding sequences 
expressed in a human NTera2 
teratocarcinoma cDNA library. 
(Drivas et al., 1990) 
TCL TC10β, 
RhoT, 
RhoJ, 
ARHJ, 
RasL7B 
Identified as a TC10-like protein in a 
database search for Rho-related 
sequences in human and murine 
expressed sequence tag (EST) data 
bases TC10-like. 
(Vignal et al., 2000) 
Wrch-1 RhoU, 
ARHU, 
Cdc42L1 
Identified by suppressive subtraction 
analysis of Wnt-1-regulated genes in 
C57MG mouse mammary epithelial cells, 
as a Wnt-1 responsive Cdc42 homolog.  
(Tao et al., 2001) 
Chp Wrch-2, 
RhoV, 
ARHV 
Identified using a two-hybrid Ras 
recruitment system that detected protein-
protein interactions, at the inner surface 
of the plasma membrane, with the Pak2 
(Aronheim et al., 
1998) 
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regulatory domain and proteins 
expressed in a myristoylated rat pituitary 
cDNA library. 
Rnd1 Rho6, 
ARHS 
Human homolog of a gene identified in a 
mixed oligonucleotide probe, 
corresponding to the Rho effector 
domain sequence (YVPTVFENYVADIE) 
and used to screen a bovine brain cDNA 
library.  The bovine cDNA was then used 
to screen and isolate the human 
counterpart. 
(Nobes et al., 1998) 
Rnd2 Rho7, 
ARHN, 
RhoN 
Human homolog of a bovine gene 
identified in a mixed oligonucleotide 
probe, corresponding to the Rho effector 
domain sequence (YVPTVFENYVADIE), 
used to screen a bovine brain cDNA 
library. The bovine cDNA was then used 
to screen and isolate the human 
counterpart. 
(Nobes et al., 1998) 
Rnd3 RhoE, 
Rho8, 
ARHE 
Identified in a yeast interaction trap 
screen for p190 RhoGAP interacting 
proteins (RhoE); Nucleotide sequence 
identity with DTAGQE GTP binding 
motif; Human homolog of a bovine gene 
identified in a mixed oligonucleotide 
probe, corresponding to the Rho effector 
domain sequence (YVPTVFENYVADIE), 
used to screen a bovine brain cDNA 
library; identified using a DNA-chip 
expression array that identified p53-
inducible genes. 
(Foster et al., 1996; 
Nobes et al., 1998; 
Ongusaha et al., 
2006) 
 
RhoBTB1  Identified as a human homolog of a gene 
encoding the RacA Rho-related protein 
in Dictyostelium discoideum; identified as 
a gene within the10q21 deletion in head 
and neck squamous cell carcinomas and 
to define candidate tumor suppressor 
genes. 
(Beder et al., 2006; 
Rivero et al., 2001) 
 
RhoBTB2 DBC2 Identified as a human homolog of a gene 
encoding a Rho-related protein in 
Dictyostelium discoideum; identified in a 
representational difference analysis as a 
gene deleted in breast cancer in 8p21.  
(Hamaguchi et al., 
2002; Rivero et al., 
2001) 
RhoH TTF, 
ARHH 
Identified as a fusion partner with 
LAZ3/BCL6 in a non-Hodgkin’s 
lymphoma cell line and cause by a t(3;4) 
translocation (Translocation Three Four). 
(Dallery et al., 1995) 
Rif ARHF, 
RhoF 
Identified in a database search in the 
human Expressed Sequence Tag 
database, encoding a Rho in filopodia 
(Ellis and Mellor, 
2000) 
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RhoD ARHD, 
RhoHP1 
Isolated by PCR amplification using 
oligonucleotides corresponding to the 
GXXXXGKS/T and WDTAGQE GTP-
binding motifs of Rab/Rho proteins, from 
mouse kidney RNA. 
(Chavrier et al., 1992; 
Murphy et al., 1996) 
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The next Rho family GTPases identified were Rac1 and Rac2, which were isolated as 
proteins encoded by genes with sequence identity to an oligonucleotide encoding the 
peptide sequence FDTAGQEDYD, corresponding to a conserved consensus GTP-binding 
motif, from Cdc42.  Analyses suggested that it was a Ras-related C3 botulinum toxin 
substrate, although this was later found not to be the case, due to contamination with Rho.  
A third member, Rac3, was discovered later in a search for Rac-related sequences by using 
the murine rac1 cDNA fragment to screen a human K562 cell line cDNA library (Haataja et 
al., 1997).  Finally, a splice variant of Rac1, designated Rac1b, was found to be expressed 
preferentially in breast and colon cancers (Jordan et al., 1999b; Schnelzer et al., 2000). 
 
Cdc42 was discovered by two independent, parallel directions of study.  Cdc42 was 
identified initially in a mutagenesis screen in S. cerevisiae as a temperature-sensitive (ts) 
mutation, cdc42-1ts, that blocked bud formation at 37°C but allowed the cell mass and 
volume to increase, resulting in greatly enlarged, unbudded cells (Adams et al., 1990).  The 
predicted amino acid sequence of Cdc42 showed strong homology with Rho (Johnson and 
Pringle, 1990).  Concurrently, a 25 kDa guanine nucleotide binding protein, designated Gp or 
G25K, was purified from bovine brain and human placental membranes with peptide 
sequences showing a high sequence similarity to S. cerevisiae Cdc42.  Subsequent 
isolation of two independent human cDNA isolates indicated the existence of two highly 
conserved (95% identical) proteins, the ubiquitously expressed Cdc42Hs (Shinjo et al., 
1990) and the brain isoform G25K (Munemitsu et al., 1990), and subsequently designated 
Cdc42p and Cdc42b, respectively.  The two Cdc42 proteins arise from alternative splicing, 
are identical in amino acids 1 to 163 but diverge from residues 163 to 191 (Marks and 
Kwiatkowski, 1996). 
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Subsequent studies identified additional members of the Rho family.  Although Cdc42 has 
no highly related isoforms, a number of Cdc42-related proteins have been identified.  These 
include TC10 (gene expressed in teratocarcinoma cells) (Drivas et al., 1990) and a TC10-
like (TCL) protein.  Chp (Cdc42 homologous protein) was discovered through its ability to 
bind to p21 activated kinases (PAK) and Wrch-1 (Wnt-1 responsive Cdc42 homolog) as a 
gene upregulated by Wnt-1 signaling (Aronheim et al., 1998; Taneyhill and Pennica, 2004). 
 
RhoG was identified as a gene stimulated by growth serum (Vincent et al., 1992), whereas 
TTF/RhoH was identified as a gene found translocated in B cell lymphomas (Dallery-
Prudhomme et al., 1997). The first member of the Rnd proteins (Rnd3/RhoE) was identified 
as a p190RhoGAP-interacting protein (Foster et al., 1996), and later studies identified the 
three Rnd proteins by low stringency hybridization screening (Nobes et al., 1998). Finally, 
the advancement of the genomic sequencing projects enabled screening of the whole 
human and murine genomes for new Rho members (e.g., Rif, RhoBTB1, RhoBTB2), which 
to date consists of 20 human genes encoding 23 proteins. 
 
Rho GTPases fall into eight subfamilies based on sequence and structure homologue: Rho 
subfamily (RhoA, RhoB and RhoC), Rac subfamily (Rac1, Rac1b, Rac2, Rac3 and RhoG), 
Cdc42 subfamily (Cdc42p, Cdc42b, TC10 and TCL), Rnd subfamily (Rnd1, Rnd2 and 
Rnd3), RhoBTB subfamily (RhoBTB1 and RhoBTB2), RhoD/RhoF, Wrch-1/Chp and RhoH 
subfamilies (Figure 1.2) (Wennerberg and Der, 2004). Out of these subfamilies, RhoH, 
RhoBTB, Wrch-1/Chp, and Rnd have characteristics that make them atypical compared to 
the Rho, Rac, Cdc42 and RhoD/RhoF subfamilies (Aspenstrom et al., 2007).  Rho GTPases 
are not found in prokaryotes, but are conserved in eukaryotic evolution, present lower 
eukaryotes (e.g., slime mold and yeast), plants, and mammals (Boureux et al., 2007). 
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Figure 1.2 Human Rho GTPases. Amino acid sequences of the G domains 
(corresponding to amino acids 5–173 of Rac1) of human Rho GTPase family members 
were aligned using ClustalX and the dendritic tree was made with TreeViewX.  The 20 
members of the Rho GTPases, including two splice variants, can be subdivided into eight 
major branches: the Rho, Cdc42, Rac, Rnd, RhoD/F, RhoU/V, RhoH, and RhoBTB 
subfamilies. 
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1.4 Regulation and function of Rho-family members. Much of our knowledge of the 
structure and biochemistry of Rho GTPases was first extrapolated from information derived 
from the study of Ras proteins.  Rho GTPases share approximately 25% amino acid identity 
with Ras, in particular in sequences important for GDP/GTP binding and regulation, effector 
binding and posttranslational lipid modifications.  Like Ras, Rho GTPases possess a set of 
consensus GDP/GTP-binding sequence elements, an effector interaction domain, and C-
terminal CAAX tetrapeptide motifs.  The general structure of Rho GTPases is comprised of 
an N-terminal G-domain involved in GTP-binding and hydrolysis, and effector binding, and a 
C-terminal membrane targeting domain (Figure 1.3). Within the G-domain lies an “insert 
sequence” positioned between residues analogous to Ras residues 122 and 123, and are 
unique to Rho GTPases (Valencia et al., 1991). Several members of the family include 
additional N- and/or C-terminal sequences.  In particular, RhoBTB1 and RhoBTB2 contain 
extensive additional C-terminal sequences that include tandem BTB (broadcomplex, 
tramtrack, bric a brac) domains, and lack the CAAX motif found on 16 of 20 Rho family 
proteins. 
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Figure 1.3 Structural domains in Rho GTPases. Highlighted residues are important for 
GTPase activity: core effector domain (purple), GTP-binding motifs (white), Rho insert 
domain (blue), hypervariable domain (stripes) and the CAAX domain (spots). The 
exchange between the GDP- and the GTP-bound states is accompanied by the 
conformational changes in Rho in two amino terminal regions switch I (which 
corresponds to Ras residues 30-38) and switch II (Ras residues 60-76). These switch 
regions are critical for proper interaction with upstream regulators such as GEFs and 
GDIs and downstream effector molecules, hence termed ‘effector region’. Another 
region involved in effector-mediated signaling is an alpha-helical ‘insert region’, 
positioned between residues corresponding to Ras residues 122 and 123, that is 
present in Rho GTPases, but not other Ras superfamily members. The hypervariable 
domain (which exhibits the greatest sequence divergence between highly related 
isoforms) and the CAAX motif (C = cysteine, A = aliphatic, X = terminal amino acid) are 
membrane targeting signals. The CAAX motif signals for a series of post-translational 
modifications to promote subcellular localization of Rho GTPases to the plasma 
membrane and other endomembranes.  
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The regulatory cycle of GTP binding and hydrolysis is similar to Ras (Figure 1.4). Switch I 
and switch II domains, corresponding to Ras residues 30-38 and 59-76, respectively, 
undergo a conformational change upon cycling between GDP and GTP that alters the 
affinity of the effector-binding domain for effectors (Vetter and Wittinghofer, 2001).  As 
described below, regulatory proteins that control Rho GTPase activity interact with switch I 
and/or II sequences.  Tumor-associated missense mutations render Ras proteins 
constitutively active (primarily at residues G12, G13 or Q61) by impairing intrinsic and GAP-
stimulated GTP hydrolysis.  
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Figure 1.4 Rho GTPase regulation and signaling.  Rho GTPases associate with 
regulators and effectors that participate in a multitude of signaling events. Extracellular 
molecules stimulate upstream receptors such as G protein-coupled receptors, receptor 
tyrosine kinases (RTK), tyrosine kinase-associated receptors (TK), and integrins that 
then activate Rho GTPases mostly through GEFs. The ‘active’ GTP Rho GTPases 
undergoes a conformation change that increases its affinity for downstream effectors 
important for many cellular processes including actin organization, motility, invasion, 
and gene expression. GAPs negatively regulate Rho GTPase function by increasing 
the intrinsic GTP hydrolysis rate, locking them in a GDP-bound state. GDIs lock Rho 
GTPases in a GDP-bound state through binding and masking their C-terminal moiety 
thereby prohibiting membrane association, nucleotide exchange and effector binding.  
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The Ras C-terminal CAAX motif (C = cysteine, A = aliphatic, X = terminal residue) was 
shown to signal a series of posttranslational modifications: farnesyltransferase catalyzed 
covalent addition of a C15 farnesyl isoprenoid lipid to the cysteine residue of the CAAX 
tetrapeptide, Ras converting enzyme (Rce1)-catalyzes proteolytic cleavage of the AAX 
residues, and isoprenylcysteine carboxylmethyltransferase (ICMT)-catalyzed 
carboxylmethylation of the farnesylated cysteine residue. The CAAX-signaled modifications, 
together with a second membrane targeting signal, either a polybasic domain, or 
palmitoylated-cysteine(s), immediately upstream of the terminal CAAX tetrapeptide motif 
facilitate Ras membrane association and subcellular localization.  The majority of Rho 
GTPases also terminate with a C-terminal CAAX motif, and additionally contain upstream 
polybasic or palmitate fatty acid-modified cysteines that are required for proper membrane 
attachment of Rho GTPases (Cox and Der, 1992; Zhang and Casey, 1996).  However, 
whereas some are modified by a C15 farnesyl group, others are modified by a related 
enzyme, geranylgeranyltransferase-I, to catalyze the addition of a more hydrophobic C20 
geranylgeranyl isoprenoid lipid.  The specific isoprenoid modification is dictated by the X 
residue of the CAAX motif, with X = L signaling for geranylgeranyltransferase-I, X = S, M, A 
or Q signaling for farnesyltransferase, and X = F for modification by both enzymes (Reid et 
al., 2004). Finally, additional C-terminal sequences adjacent to the CAAX motif (e.g., basic 
residues, palmitoylated cysteines) dictate the precise subcellular localization of Rho 
GTPases.  Rho GTPases exhibit a diversity of subcellular locations, including the plasma 
membrane, endosomes, the Golgi and the endoplasmic reticulum (Vega and Ridley, 2007).    
 
Regulator of Rho GTPases. Studies in the early 1990’s identified three classes of Rho-
specific regulatory proteins that control the GDP/GTP Rho GTPase cycle: guanine 
nucleotide exchange factors (GEFs) (Rossman et al., 2005), GTPase-activating proteins 
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(GAPs) (Moon and Zheng, 2003), and GDP dissociation inhibitors (GDIs) (DerMardirossian 
and Bokoch, 2005) (Figure 1.5).  Since GDP and GTP are at mM levels in cells, and Rho 
GTPases have low pM binding affinities for guanine nucleotides, Rho GTPases are always 
nucleotide-bound.  GEFs accelerate the intrinsic exchange activity of Rho GTPases and 
catalyze the release of bound GDP, resulting in the formation of active GTP bound state of 
the GTPase because GTP levels are ~10-fold higher than GDP in cells (Pilz et al., 1997). 
GTPase inactivation involves GAP stimulating the low intrinsic GTP hydrolytic activity, 
converting GTPases to the inactive GDP-bound state.  As reflected in their name, GDIs 
block the dissociation of guanine nucleotide from the Rho GTPase, but additionally possess 
other Rho GTPase regulatory functions (Gosser et al., 1997; Hoffman et al., 2000; Keep et 
al., 1997).  Interestingly, there are Ras-specific GEFs and GAPs, but no known GDIs for 
Ras.  
 
RhoGDIs.  In 1990, the first RhoGDI was identified and characterized by Takai and 
colleagues as the first regulator of Rho GTPases (Fukumoto et al., 1990; Ueda et al., 1990). 
RhoGDIs are generally considered as negative regulators of Rho GTPase activity by their 
ability to (1) prevent GDP dissociation and GEF-stimulated exchange, (2) prevent intrinsic 
and GAP-stimulated GTP hydrolysis and effector binding, and (3) membrane association.  In 
the latter function, RhoGDI binds and masks the C-terminal isoprenyl group of GTPases via 
an immunoglobulin-like domain and N-terminal regulatory portion of RhoGDI binds the 
switch I and switch II regions of the Rho GTPases, thereby locking Rho GTPases in an 
inactive complex in the cytosol (Gosser et al., 1997; Hoffman et al., 2000; Keep et al., 1997).  
However, RhoGDIs can also act as positive regulators via targeting Rho GTPases to 
subcellular membranes where they interact with different effectors or protect Rho GTPases 
from caspase degradation (Simpson et al., 2004). 
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There are three RhoGDI isoforms in humans: RhoGDI1 (GDI/GDIα), RhoGDI2 
(LyGDI/D4GDI/GDIβ), and RhoGDI3 (GDIγ). RhoGDI1 and RhoGDI2 have a 74% conserved 
sequence identity in the 178 COOH-terminal residues, whereas the same region in 
RhoGDI3 demonstrated 63% identity (Figure 1.5) (Olofsson, 1999). RhoGDI1 protein was 
first purified from rabbit intestine and bovine brain cytosols as inhibiting GDP/GTP binding to 
RhoB. The corresponding human cDNAs were isolated and the locus was assigned to 
17q25.3-25-3 (Leffers et al., 1993). RhoGDI1 protein contains 204 amino acids and is 
ubiquitously expressed. RhoGDI2 was identified as a human protein specifically expressed 
in human and murine hematopoietic tissues and predominately in B- and T-lymphocyte cell 
lines (Lelias et al., 1993). RhoGDI2 is composed of 200 amino acids. RhoGDI3 was first 
found as a protein preferentially expressed in murine brain tissues and later a human 
homologue was identified and mapped to locus 16p13 (Zalcman et al., 1996). RhoGDI3 is 
expressed preferentially in lung, testes and brain (Adra et al., 1997). RhoGDI3 contains 225 
amino acids. Different RhoGDI isoforms may have distinct and overlapping biological 
functions that are not fully understood. However, aberrant expression of RhoGDI2 has been 
seen in human cancers (Berman et al., 2004; Gildea et al., 2002; Theodorescu et al., 2004; 
Zhang and Zhang, 2006). 
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Figure 1.5 The RhoGDI family. Three mammalian Rho family-specific GDI proteins 
have been identified, each exhibiting a high degree of primary sequence conservation 
(indicated as percent identity). The domain architecture of the GDIs described in the 
text is illustrated in relation to the primary sequence, with the amino-terminal regulatory 
arm shown in orange and the immunoglobulin-like domain in blue (residue 74 marks 
the beginning of the first β strand in the immunoglobulin like domain of RhoGDI and is 
marked by the arrow). The approximate locations of residues important for binding 
RhoGDI are indicated in yellow. The unique helical region at the amino-terminus of 
RhoGDI3 is shown in pink.  Figure reproduced from (Olofsson, 1999). 
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RhoGDI binding specificity to Rho GTPases is different for each isoform but still remains 
largely uncharacterized for the less studied Rho family proteins (DerMardirossian and 
Bokoch, 2005) (Figure 1.6), with some Rho family GTPases (e.g., Wrch-1 and Wrch-2/Chp) 
not regulated by RhoGDIs (Chenette et al., 2006). The localization of the RhoGDIs may 
dictate interaction with specific Rho family GTPases. For instance, RhoGDI1 and RhoGDI2 
are primarily cytosolic and interact with Cdc42, Rac1, and RhoA, whereas RhoGDI3 is 
localized to vesicular membranes and exhibits specificity for RhoB and RhoG (Gorvel et al., 
1998). Also, each of the RhoGDI isoforms binds with different affinities to the Rho GTPases.  
Recombinant RhoGDI2 was found to be less efficient by 10 to 20 fold than RhoGDI1 to 
inhibit GDP/GTP exchange or membrane dissociation of RhoA, Rac1, and Cdc42 (Platko et 
al., 1995). A single residue point mutation in either RhoGDI1 or RhoGDI2 (Ile 177 in 
RhoGDI1/Asp 174 in RhoGDI2) was demonstrated to be responsible for much of the 
difference in the binding affinities of these proteins (Figure 1.5). 
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Figure 1.6 RhoGDIs associate with different Rho GTPases (35, 58-69). The Rho 
GTPases that have not been tested for interaction with RhoGDIs are TCL, Rnd1, 
Rnd2, RhoD, Rif, RhoBTB1, and RhoBTB2. Adapted from (DerMardirossian and 
Bokoch, 2005). 
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How RhoGDIs themselves are regulated remains largely unexplored, although is thought to 
be via direct interaction with displacement factors or by phospho-regulation of their 
interaction with Rho GTPases. Recent studies have demonstrated that guanine nucleotide 
displacement factors (GDFs) as well as RhoGDI-binding proteins regulate the subcellular 
location of the RhoGDI-GTPase complex (DerMardirossian et al., 2006). RhoGDI1 is 
phosphorylated by Pak1 on two sites located on the external surface of the hydrophobic cleft 
in which Rho GTPase prenyl group binds (DerMardirossian et al., 2004). After 
phosphorylation, Rac1 but not RhoA is released from cytosolic RhoGDI1 complexes leading 
to activation by exchange factors. Recently, RhoGDI1 and RhoGDI2 were discovered to be 
phosphorylated by Src tyrosine kinases at one site that lies at the RhoGDI-Rho GTPase 
binding interface (Figure 1.7) (DerMardirossian et al., 2006).  This phosphorylation 
dramatically decreases the binding of RhoGDI to RhoA, Rac1, and Cdc42. In addition to 
Pak1 and Src kinases, the ERM (Erzin, Radixin, Moesin) that are implicate in cortical actin 
reorganization events, the p75 neurotrophin receptor, and the tyrosine kinase Etk have been 
described to induce the release of RhoA from RhoGDI1 (Kim et al., 2002; Takahashi et al., 
1997; Yamashita and Tohyama, 2003). Finally, lipids have been shown to decrease the 
affinity of RhoGDI1 for RhoA and Rac1.  In addition caspase-mediate cleavage of RhoGDI2 
creates truncated, functionally-divergent variants of RhoGDI2 that may render RhoGDI2 
functionally inactive, and thus potentially impacting the activity of Rho GTPases (Essmann 
et al., 2000; Krieser and Eastman, 1999; Na et al., 1996).  Since the stoichiometry of 
RhoGDIs and Rho GTPases is critical for dictating their degree of association, regulation of 
RhoGDI expression is also likely to be important.  Hence, the regulation of RhoGDIs is 
complex and multi-faceted. 
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Figure 1.7 GDIs regulate cytosol-membrane cycling of Rho GTPases. RhoGDI, 
through its immunoglobulin like domain, binds and masks the C-terminal 
geranylgeranyl (GG) membrane-targeting moiety of Rho GTPases. RhoGDI also binds 
the switch I/II regions in the Rho GTPase, which can then prohibit effector and 
GEF/GAP interactions. This result inhibits GDP dissociation and localizes GTPases to 
the cytosol in inert forms unable to interact with GEFs. Guanine nucleotide 
displacement factors (GDFs), such as Pak or Src kinases, phosphorylate GDI and 
release the Rho GTPase recycling it to the membrane for activation (DerMardirossian 
and Bokoch, 2005). 
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RhoGEFs: There are two families of human RhoGEFs. The largest family, the Dbl family, is 
comprised of 69 human members (Rossman et al., 2005; Schmidt and Hall, 2002).  It’s 
name is because the first member was discovered with the identification of the Dbl 
oncoprotein, as a potent transforming gene identified in a genomic DNA (derived from a 
diffuse B-cell lymphoma) gene transfer assay using the NIH 3T3 mouse fibroblasts focus 
formation transformation assay (Eva and Aaronson, 1985). The discovery that Dbl functions 
as a RhoGEF was made by Cerione and colleagues in 1991 (Hart et al., 1991).  Similar 
genomic or cDNA expression screens for transforming genes identified additional members, 
including Vav (Katzav et al., 1989), Ect2 (Miki et al., 1993), Tim (Chan et al., 1994), Ost/Dbs 
(Horii et al., 1994; Whitehead et al., 1995a), Lbc (Toksoz and Williams, 1994), Lsc 
(Whitehead et al., 1996), Lfc (Whitehead et al., 1995b), and Net1 (Chan et al., 1996). Tiam1 
was identified in a screen for invasion inducing gene (Habets et al., 1994). The Dbl 
homology (DH) catalytic domain is followed by a pleckstrin homology (PH) domain. Although 
PH domains are found in many other classes of signaling proteins, the invariant C-terminal 
association of this domain with the DH domain seen in essentially all Dbl family RhoGEFs 
reflects their critical role in facilitating DH domain catalytic activity.  The roles of the PH 
domain are diverse and varied, and include interaction with phospholipids that may activate 
the catalytic domain (DH) of GEFs or promote localization to the plasma membrane.  Dbl 
family RhoGEFs also possess a plethora of additional protein- and lipid-interaction domains 
that facilitate their regulation by upstream signaling networks. 
 
The second family of RhoGEFs are comprised of 11 DOCK proteins (also called CZH 
proteins) related to Dock180 (Cote and Vuori, 2002; Meller et al., 2005). Dock180 (180-kDa 
protein) was identified initially in 1996 as a binding partner for the Crk adaptor protein 
(Hasegawa et al., 1996).  The Drosophila ortholog, Myoblast city, was identified originally as 
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a gene involved in muscle development (Rushton et al., 1995), and later, as a protein with 
strong homology with DOCK180 and shown essential for myoblast fusion and dorsal closure 
(Erickson et al., 1997).  The C. elegans ortholog of Dock180, Ced-5, was identified as a 
protein required for cell migration and phagocytosis (Wu and Horvitz, 1998). Although earlier 
studies established Dock180 and related proteins as Rac activators and can interact with 
nucleotide-free Rac, the first biochemical evidence that it functions as a GEF was not made 
until 2002 (Brugnera et al., 2002; Cote and Vuori, 2002).  A second family member, 
zizimin1, was identified as a Cdc42-interacting protein (Meller et al., 2002). Database 
homology searches reveal that Dock180 and zizimin1 are members of a novel family 
conserved in a wide variety of eukaryotes. DOCK proteins are characterized by two regions 
of high sequence conservation, designated Dock-homology region-1 and -2 (DHR1 and 
DHR2; also called CZH1 and CZH2/DOCKER, respectively) that are distinct in sequence 
from the DH domains. DOCK family RhoGEFs also contain additional domains, independent 
of the domains that promote exchange of nucleotides that are able to influence and 
determine their activation by upstream signals and their activation of downstream signaling 
to different effector molecules. 
 
RhoGAPs. The discovery of GAPs for Ras proteins (p120 RasGAP and NF1 neurofibromin) 
prompted interest in searching for GAPs specific for Rho GTPases. The first identification of 
GAP activity for Rho GTPases was made in 1989 by Hall and colleagues (Garrett et al., 
1989).  They identified a 29 kDa protein with GAP activity for RhoA and subsequent limited 
protein sequence analyses revealed homology with the Breakpoint cluster protein (Bcr) and 
BCR-related N-chimaerin protein (Diekmann et al., 1991).  They then showed that Bcr and 
N-chimaerin possessed GAP activity for Rac1. These studies helped define a ~150 amino 
acid RhoGAP catalytic domain that is distinct from the catalytic domains of GAPs for other 
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Ras family GTPases.  Recent human genome analysis has unveiled up to 70 RhoGAPs in 
humans (Tcherkezian and Lamarche-Vane, 2007). RhoGAPs regulate different Rho family 
members, with some very specific and others active for multiple GTPases. Thus, similar to 
GEFs, the number of RhoGAPs greatly outnumber the number of Rho GTPases, and some 
Rho GTPase family members may not be regulated by GAPs.  It is not clear why there are 
so many RhoGAPs and their nodes of regulation are less defined than RhoGEFs. 
Nevertheless, similar to GEFs, GAPs are usually multidomain proteins that suggest their 
regulation by distinct signaling mechanisms and their function as protein scaffolds and 
signaling integrators. For example, Rac-mediated phosphorylation of p190RhoGAP results 
in the association with p120-catenin to locally inhibit Rho activity and allow formation of 
adherens junctions (Nimnual et al., 2003).  In human cancers, the expression of DLC-1 and 
related isoforms is lost in human cancers, supporting a tumor suppressor function for some 
RhoGAPs (Durkin et al., 2007). 
 
Atypical Rho GTPases. The Rho GTPases subfamilies, RhoH, Rnd, Wrch1/Chp and 
RhoBTB have structural and biochemical characteristics that distinguished them from the 
three classical Rho GTPases (RhoA, Rac1 and Cdc42) and hence they are commonly 
referred to as atypical Rho GTPases (Aspenstrom et al., 2004; Chardin, 2006; Wennerberg 
and Der, 2004). Some arose late in evolution and exhibit more restricted tissue expression, 
suggesting more specialized roles in cell physiology (Boureux et al., 2007).  Some are 
functionally different from the classical Rho GTPases and rarely undergo regulation by 
GDP/GTP cycling.  For example, Rnd3/RhoE possesses divergence at residues normally 
required for efficient intrinsic and GAP-stimulated GTPase activity (analogous to Ras 
residues G12 and Q61), and was shown to persist in the GTP-bound state (Foster et al., 
1996).  Similarly, RhoH was shown to have GTPase-inactivating amino acid substitutions 
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resulting in the constitutively activated GTP-bound state (Li et al., 2002). Other atypical Rho 
GTPases, such as RhoBTB1 and RhoBTB2/DBC2 are also expected to be GTPase-
deficient. Therefore, instead of having GEFs and GAPs to regulate their on/off cycling, they 
are often regulated by gene expression levels.  Posttranslational mechanisms, such as 
phosphorylation or targeted destruction such as proteasomal degradation may also be 
mechanisms that regulate their activities. For example, Rnd3 function has been found to be 
regulated by phosphorylation by ROCK and by protein kinase C alpha (Madigan et al., 
2009).  
 
Wrch-1 and Chp do not have amino acid replacements at residues required for GTPase 
activity but do exhibit enhanced intrinsic nucleotide exchange activity (Aronheim et al., 1998; 
Shutes et al., 2004). Therefore, it is not clear whether their activities will be regulated by 
GEFs and GAPs.  The Rac1 splice variant (Rac1b) also has elevated intrinsic exchange 
activity and resides in the GTP-bound conformation (Schnelzer et al., 2000). 
 
The more recently identified Rho GTPases subfamily, RhoBTB1 and RhoBTB2/DBC2, are 
much larger and have additional domains when compared to the classical Rho GTPases 
(Rivero et al., 2001). They contain two BTB domains that promote protein:protein 
interactions and is a Cullin 3 binding partner involved in proteosomal degradation (Wilkins et 
al., 2004). Finally, the dysfunctional regulation of atypical Rho GTPases (e.g. Wrch-1, 
RhoBTB2 and Rac1b) may be involved in the pathogenesis of diseases such as cancer.  
 
1.5 Upstream signaling, downstream effectors, and Rho biological processes. 
Although the first Rho GTPases were identified in 1985, it was not until 1992 that the Rho 
family was brought into the spotlight when they were implicated as key regulators of 
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extracellular ligand-mediated changes in actin reorganization through activation of cell 
surface GPCR or RTK receptors. Two seminal studies by Ridley, Hall and colleagues 
established that Rho and Rac were important for extracellular stimulus-regulated actin 
cytoskeletal reorganization (Ridley and Hall, 1992; Ridley et al., 1992). The key 
observations were that lysophosphatic acid (LPA) was the factor in calf serum that 
stimulated GPCR- and Rho-dependent formation of actin stress fibers, and that platelet-
derived growth factor (PDGF) RTK-stimulated membrane ruffling could be blocked by a 
Rac1 dominant negative protein.  Subsequent studies also linked bradykinin-stimulated 
GPCR signaling to activation of Cdc42, to cause formation of actin-rich, membrane 
microspikes (filopodia) (Kozma et al., 1995; Nobes and Hall, 1995). The ability of RhoA, 
Rac1, and Cdc42 to regulate diverse signaling cascades linking membrane receptors to the 
construction of distinct actin structures has been confirmed in a mammalian, worms, yeast, 
flies and many other organisms.   
 
In addition to regulation of actin cytoskeletal organization, Rho GTPases also participate in 
the regulation of many other signal transduction pathways beyond actin regulation.  In 1991, 
Rac was shown to regulate the NADPH oxidase complex and superoxide production in 
neutrophils (Abo et al., 1991).  In 1995, studies implicated Rho GTPases as regulators of 
the p38 and JNK stress-activated mitogen-activated protein kinase (MAPK) cascades (Coso 
et al., 1995; Minden et al., 1995) and transcription factor activity and gene transcription (Hill 
et al., 1995).  Rho GTPase signaling was shown to be critical regulators of cell cycle 
progression (Olson et al., 1995; Yamamoto et al., 1993).   
 
Rho GTPases were also shown to comprise signaling networks involving other GTPases 
(Ridley and Hall, 1992; Ridley et al., 1992).  In particular, in 1995, Rac, Rho and Cdc42 
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were found to be key mediators of Ras-induced oncogenic transformation (Khosravi-Far et 
al., 1995; Qiu et al., 1997; Qiu et al., 1995a; Qiu et al., 1995b).  Similarly, GPCR-mediated 
growth transformation also involved activation of Rho GTPases (Martin et al., 2001; Zohn et 
al., 1998).  Thus, like Ras, Rho GTPases function as signaling nodes, where divergent 
upstream signaling stimuli converge to activate Rho GTPase function, and where activated 
Rho GTPases then interact with multiple downstream effectors to regulate cytoplasmic 
signaling networks that control a multitude of cytoplasmic and nuclear events.   
 
Similar to Ras, each Rho GTPase interacts with multiple functionally-diverse downstream.  
Rho GTPase effectors have been identified by a variety of experimental approaches.  These 
include yeast two-hybrid library protein interaction screens, biochemical approaches and 
database searches for consensus “Rho GTP-dependent binding domains/motifs (RBDs) 
conserved in subsets of effectors. Below we highlight some of the key findings that have laid 
the foundation for the effectors that facilitate Rho GTPase signaling networks.  In light of the 
diversity of functions regulated by Rho GTPases, it is not surprising that each interacts with 
a spectrum of functionally diverse effectors. 
 
Linking extracellular signals with Rho GTPases.  As described above, extracellular 
ligand induced signaling from cell surface receptors to Rho GTPases was first described by 
Ridley, Hall and colleagues (Ridley and Hall, 1992; Ridley and Hall, 1994; Ridley et al., 
1992). At this time, the precise links that connected activated RTKs or GPCRs with Rho 
GTPases were not known.  Although the involvement of Dbl family proteins as Rho GEFs 
was not known, the ability to block Rho GTPase activation by dominant negative mutants of 
Rho GTPases (e.g., Rac1 S17N), that form nonproductive complexes with RhoGEFs (Feig, 
1999), implicated RhoGEFs as the key links (Figure 4). 
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An additional clue that RhoGEFs may link extracellular signals with Rho GTPases came 
from observations that the removal of the N-terminal sequences of Dbl, Vav, Asef, Taim1, 
Ect2, and other Dbl family RhoGEF members leads to their constitutive activation when 
expressed in vivo (Katzav et al., 1991; Kawasaki et al., 2000; Miki et al., 1993; Ron et al., 
1989; van Leeuwen et al., 1995). This suggested that their N-terminal sequences functioned 
as autoinhibitory regulatory domains that block RhoGEF catalytic activity. Therefore, 
activation of GEF is through the relief of autoinhibition via posttranslational modifications or 
by binding to other proteins via their N-terminal sequences.  These N-terminal sequences 
often contain distinct domains and motifs that suggest their recognition by diverse upstream 
signals. 
 
The first elucidation of how upstream signals cause Rho GTPase activation via activation of 
a RhoGEF came from studies of Vav.  Vav has been implicated downstream of many 
receptors, including the RTKs stimulated by the epidermal growth factor and platelet-derived 
growth factor peptides (Bustelo, 2000).  After receptor stimulation, Vav is phosphorylated by 
Src and Syk tyrosine kinases families that then stimulate Vav activation of RhoA, RhoB, 
RhoG, Rac1, and Cdc42 (Abe et al., 2000; Crespo et al., 1997; Han et al., 1997).  The Vav1 
DH domain is autoinhibited by interaction with an adjacent N-terminal acidic region that 
includes tyrosine residues.  When these residues are phosphorylated, autoinhibition is 
relieved and the catalytic activity of the DH domain is activated (Aghazadeh et al., 2000).  A 
similar phosphorylation activation mechanism is also seen with Tim and other RhoGEFs 
(Yohe et al., 2007). 
 
LPA binds to Edg/LPA GPCR and results in the activation of Gα12/13 subunits (Hart et al., 
1998; Kozasa et al., 1998).  The activated GTP-bound Gα12/13 subunits bind to the RGS 
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(regulators of G protein signaling) domain of a family of RhoGEFs (p115RhoGEF, LARG, 
and PDZ-RhoGEF) resulting in their relocalization to the cell surface and subsequent 
activation (Fukuhara et al., 2001).  These RhoGEFs are activators of RhoA and actin stress 
fiber formation. 
 
Some RhoGEFs are regulated by other protein-protein interactions.  Tiam1 which contains a 
Ras binding domain similar to that found in the Raf serine/threonine kinase Ras effectors, is 
activated upon binding to GTP-bound Ras (Lambert et al., 2002).  The Asef RhoGEF, an 
activator of Cdc42, contains an N-terminal binding domain for the APC tumor suppressor 
(Kawasaki et al., 2000).  Asef is activated by the binding of wild type but not tumor-
associated mutant APC (Mitin et al., 2007).   
 
In addition, investigations dissecting the pathways from growth factor receptors to Rac 
activation uncovered growth factor-induced membrane ruffling was blocked by 
phosphatidyinositol 3-kinase (PI3K) inhibitors (Nobes and Hall, 1995).  Subsequent studies 
revealed some RhoGEFs are activated by PI3K activation and production of 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) (Schmidt and Hall, 2002).  For example, the 
P-Rex1 Rac-specific GEF is activated by PIP3 association with its PH domain (Welch et al., 
2002).  However, full activation involves coordinated activation by heterotrimeric G βγ 
subunits, to promote membrane association (Barber et al., 2007). Lastly, Rho proteins are 
not only regulated by receptor tyrosine kinases and GPCRs, but also cell adhesion 
molecules such as integrins, cadherins, and Ig superfamily members (Braga, 2002; DeMali 
et al., 2003; Thompson et al., 2002).  The pathways signaling from these cell surface 
molecules to cause Rho GTPase activation remain to be fully understood.     
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Actin cytoskeleton regulation.  The best characterized function of Rho GTPases is their 
regulation of distinct actin cytoskeleton reorganization and cellular processes (Jaffe and 
Hall, 2005). Previous findings showed that in fibroblasts the activation of RhoA, Rac1, and 
Cdc42 induce the assembly of actin stress fibers and focal adhesion assembly, actin 
accumulation at the leading edge of migrating cells and lamellipodia formation, and actin 
microspikes and filopodia formation, respectively.  There is now considerable, although 
incomplete, knowledge of the immediate and indirect effectors that facilitate Rho GTPase 
regulation of actin.  Both Rac and Cdc42 utilize members of the WASP family to regulate the 
Arp2/3 complex, which facilitates actin filament formation.  Rho interaction with the mDia1 
diaphanous-related formins promotes actin filament elongation.  Rho activation of the ROCK 
serine/threonine kinases (also called ROK) also promotes actin stress fiber formation. 
 
In 1996, WASP was discovered to interact with Cdc42 and stimulated actin polymerization 
(Kirchhausen and Rosen, 1996). Purification of proteins required for Cdc42 actin 
polymerization in cell extracts revealed the Arp2/3 complex, important for nucleation during 
actin polymerization, and N-WASP (WASP homologue) (Bi and Zigmond, 1999). 
SCAR/WAVE was identified as a component of the Arp2/3 complex via yeast-two hybrid 
screen with p21 (member of Arp2/3 complex) (Machesky and Insall, 1998). In 2000, Rac 
was shown to associate with WAVE and Arp2/3 through IRSp5 (Miki et al., 2000). Overall, 
there are a number of targets downstream of Rho and the importance of each is highly 
complex and variable depending on circumstances such as environment and cell type. 
Future studies will more clearly elucidate connections between Rho proteins and actin 
cytoskeletal organization. 
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Protein kinase effectors.  Lim and colleagues identified in 1993 the first Rac and Cdc42 
downstream target, the serine/threonine PAK (Manser et al., 1994). These targets were 
discovered by the selection of proteins that were in a complex with GTP-bound (‘active’) but 
not GDP-bound (‘inactive’) Rac or Cdc42. Several cytoskeletal targets have been identified 
downstream of PAK. These include LIM kinases (LIMK), which phosphorylate the actin 
depolymerizing protein, cofilin, inhibiting its function (Maekawa et al., 1999). This inhibition 
stabilizes actin filament arrays such as stress fibers.  
 
Following PAK, in 1996 several groups discovered RhoA-binding kinases (ROCK I and II) 
downstream of RhoA.  A number of Rho effectors were identified via yeast two-hybrid 
screens, the first being rhoteckin and rhophilin (Reid et al., 1996; Watanabe et al., 1996). 
Rho targets have also been identified through database mining such as protein-kinase-N 
was identified through its homology to rhophilin (Watanabe et al., 1996).  ROCK was the first 
target shown to affect actin organization (Leung et al., 1996). ROCK elevates myosin light 
chain (MLC) phosphorylation by inhibiting the MLC phosphatase (Chrzanowska-Wodnicka 
and Burridge, 1996). Subsequent work established that ROCK is able to directly 
phosphorylate the regulatory MLC and enhance myosin activation. In addition, ROCK 
activates LIMK to lead to inhibition of cofilin causing actin stabilization. These studies 
established that Rho promotes myosin contractility and drives the formation of stress fibers 
and focal adhesions (Ridley, 1999).  
  
1.6 Rho GTPases and RhoGDIs in cancer. Rho GTPases are aberrantly deregulated in 
cancer by indirect mechanisms such as protein overexpression or the misregulation of 
regulatory proteins (e.g., GEFs, GAPs and RhoGDIs).  RhoA and RhoC protein levels are 
significantly elevated in many different tumor types including ovarian, especially during the 
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progression to more invasive and metastatic forms (Horiuchi et al., 2003).  Constitutively 
active RhoA in cells results in increased invasion or transformation depending on cell type.  
RNAi knockdown of RhoA and RhoC individually in SUM-159 cells, highly invasive breast 
cancer cell line, showed RhoA impedes whereas RhoC stimulates invasion.  Furthermore, 
RhoC is essential for metastasis but not for primary tumor formation in a mouse mammary 
adenocarcinoma model. In addition, RhoA, RhoB, and Rac are essential for Ras-mediated 
transformation.   Many Dbl family Rho GEFs, were identified initially in screens for novel 
transforming (e.g., Dbl, Vav, Ect2) or invasion-inducing (Tiam1) oncogenes (Habets et al., 
1994; Michiels et al., 1995), although their activation were due to lab-induced artifacts and 
where not found in the original tumor cells.  However, mutations in Tiam1, leading to 
constitutive activation, have been reported in renal carcinomas (Engers et al., 2000).  In 
addition, other RhoGEFs were identified as proteins whose genes are rearranged in human 
leukemias (e.g., LARG, BCR) (Reuther et al., 2001).  DLC proteins, that function as 
RhoGAPs, are deleted or silenced in a variety of human cancers (Yuan et al., 2004).  
Finally, RhoGDI expression levels have been linked to more invasive phenotypes in different 
cancers (Berman et al., 2004; Gildea et al., 2002; Theodorescu et al., 2004; Zhang and 
Zhang, 2006).  
 
Downstream effectors of Rho GTPases promote oncogenesis through activation of the p38 
or JNK MAPK pathways. RhoA, Rac1, and Cdc42 regulate serum response factor (SRF), 
which is a transcriptional transactivator that controls expression of immediate early genes 
(e.g., c-fos) important for proliferation and growth. SRF requires a co-activator, MAL, which 
in response to Rho activation translocates from the cytosol to the nucleus. RhoA activates 
SRF the strongest compared to Rac and Cdc42. Also, RhoA, Rac, and Cdc42 activate JNK, 
p38, and ERK1/2 MAPK, which then activate transcription factors (e.g., c-Jun, Elk-1) 
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important for many cellular processes including proliferation and invasion. In addition, Rho 
GTPases promote cell cycle progression through upregulated cyclin D1 gene transcription 
and cyclin D1 reduced cellular adhesion and promotes migration. For instance, Rac can 
activate Pak/JNK, which then activates NF-κB (important for cell survival), promoting cyclin 
D1 expression.  Cyclin D1 promotes G1 progression by a cyclin-dependent kinase-
dependent mechanism and inactivating the Rb tumor suppressor, leading to activation of the 
E2F transcription factor and stimulation of genes that promote cell proliferation. 
 
RhoGDI2 is differentially expressed in human tumors and may be involved in 
oncogenesis.  Several analyses have implicated altered RhoGDI2 expression in cancer 
progression and growth, although tumor type-specific consequences are seen (Table 1.2).  
RhoGDI2 was demonstrated to be downregulated in Hodgkin’s lymphoma cells when 
compared with non-Hodgkin’s lymphoma cells (Ma et al., 2007).  The loss of RhoGDI2 
expression may contribute to the apoptotic resistance of Hodgkin’s lymphoma cells. 
Theodorescu and colleagues reported that decreased RhoGDI2 expression was associated 
with a more invasive variant of the HRAS mutation positive T24 bladder cancer cell line 
(Gildea et al., 2002).  Ectopic restoration of RhoGDI2 expression in this bladder cell line 
caused the decrease when assayed by tail vein inoculation-induced lung metastasis 
invasion in mice.  Furthermore, they performed microarray analyses on an additional 105 
primary tumors from lung, prostate, breast, colon, rectum, kidney, bladder and liver, and 
found that loss of RhoGDI2 gene expression was associated with advanced tumor stage 
and grade.  These observations suggest a role for a loss of RhoGDI2-mediated Rho 
activation in metastasis and invasion.  To elucidate a possible mechanism by which 
RhoGDI2 loss may promote invasion, this group used microarray analysis and identified 
many genes affected by RhoGDI2 reconstitution in the lung metastatic T24 bladder cancer 
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cell line (Titus et al., 2005). They identified the loss of expression of neuromedin U and 
enothelin-1 (ET-1), secreted vasoconstrictors. Based on these studies, it has been 
suggested that RhoGDI2 regulates apoptosis in Hodgkin’s lymphoma and is a metastasis 
suppressor in bladder cancer. 
 
Other studies have suggested that RhoGDI2 can also be associated with advanced tumor 
stage or increased metastatic potential of tumor cell lines. For example, RhoGDI protein 
(isoform unidentified) was identified via proteomic analyses to be overexpressed in invasive 
ovarian cancers when compared to non-invasive ovarian cancer patient tissues (Jones et 
al., 2002).  During the progression from benign ovarian epithelium to invasive carcinoma, 
there was a loss of repression of RhoA through dissociation from RhoGDI (Berman et al., 
2004).  This suggests not only RhoGDI expression, but also the release of RhoGDI via 
mechanisms such as phosphorylation by GDFs may contribute to ovarian oncogenesis. In 
addition, RhoGDI2 mRNA levels were found to be significantly higher in ovarian 
adenocarcinoma that in benign adenoma and the upregulation was correlated with tumor 
malignancy (Tapper et al., 2001). Another study showed that RhoGDI2 expression levels 
were significantly higher in tumor compared to benign breast cancer cell lines. The 
knockdown of RhoGDI2 in the highly invasive and metastatic MDA-MB-231 breast 
carcinoma cells resulted in decreased motility and invasion in vitro and abrogated the tumor 
growth and lung metastasis of MDA-MB-231 cells in a xenograft model (Zhang and Zhang, 
2006). The adhesion protein, β1-integrin, and the extracellular degradation protein, matrix 
metalloproteases 9, expressions were decreased in the invasive MDA-MB-231 and BT549 
breast cancer cells with RhoGD2 knocked down (Zhang and Zhang, 2006).  However, the 
clinical relevance of RhoGDI2 expression in breast cancer models remains to be 
determined. Schunke et al. suggested that RhoGDI2 expression levels are not associated 
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with overall survival (Schunke et al., 2007). However, Wen et al. demonstrated that lymph 
node metastatsis-positive breast tumors have elevated levels of RhoGDI2 expression 
compared with lymph node metastasis-negative tumors (Jiang et al., 2003). Another study 
revealed biphasic expression of RhoGDI2 with progression of mammary epithelial 
proliferation (Hu et al., 2007). In gastric cancer, RhoGDI2 protein was found higher in gastric 
tumor tissues than normal gastric tissues and the expression level of RhoGDI2 correlated 
with lymph node metastasis (Cho et al., 2009). Overexpression of RhoGDI2 in SNU-484 and 
SNU-719 cells significantly increased invasiveness, whereas depletion of RhoGDI2 in SNU-
638 and MKN-28 cells suppressed invasion in vitro. In SNU-638 cells, forced expression of 
RhoGDI2 increases tumor growth, angiogenesis, and lung metastasis. VEGF-C was 
identified as a target gene for RhoGDI2 in gastric cancer cells. The sometimes opposing 
functions of RhoGDI2 may reflect tumor cell context differences and may be due to 
differential consequences on different Rho family GTPases. Since some Rho family 
GTPases may act as oncoproteins whereas others may act as tumor suppressors, RhoGDI2 
alterations may impact different sets of Rho GTPases in different tumor settings. Therefore, 
more comprehensive studies are required to fully elucidate the role and clinical relevance of 
RhoGDI2 in different cancer types.  
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Table 1.2  Reported expression of RhoGDI2 in different cancer types 
Tumor Expression Correlation Rac1 
regulation 
Regulated genes 
 
Ovarian Upregulation Stage Unknown 
 
Unknown 
 
Bladder Downregulation Survival, 
metastasis 
Increase 
(T24T) 
Endothelin-1 downregulated 
Neuromedin downregulated 
Breast Upregulation Metastasis Decrease 
(MDA-MB-231) 
β1-integrin upregulated 
Cox-2 upregulated 
Hodgkin’s 
lymphoma 
Downregulation Apoptosis Not reported Not reported 
Stomach Upregulation Stage, 
metastasis 
Increase 
(SNU-484) 
VEGF-C upregulated 
 
Several studies suggested that RhoGDI expression may modulate tumor cell sensitivity to 
cytotoxic drugs.  In a genomic microarray study, RhoGDI2 overexpression correlated to 
paclitaxel resistance in ovarian cancers (Goto et al., 2006). Their immunohistochemical 
staining analyses of 22 serous ovarian cancer tissues from patients who received paclitaxel-
based chemotherapy found that RhoGDI2 overexpression was observed significantly more 
frequently in non-responders than in responders.  They concluded that RhoGDI2 expression 
might be a biomarker of paclitaxel resistance not only in paclitaxel-resistant cell lines, but 
also in clinical samples.  However, no mechanistic analyses were done in this study to 
establish a causal relationship. RhoGDI2 is known to be a substrate for cleavage by 
caspase-3, resulting in a cleaved product that translocates to the nucleus (Krieser and 
Eastman, 1999). The mechanism by which RhoGDI2 protects cells from apoptosis is not 
fully understood (Essmann et al., 2000). A hypothesis is that RhoGDI2 may regulate 
proapoptotic signaling pathways (e.g., JNK, p38) regulated by Rho GTPases or increased 
RhoGDI2 may block caspase-3-mediated cleavage of Rac1, important for cell survival. 
 
Mechanisms underlying the involvement of RhoGDI2 in tumorigenesis and 
metastasis. Recently, Rac GTPases have been demonstrated to be involved in the 
regulation of RhoGDI2-mediated cancer metastasis. For instance, RhoGDI2 was 
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demonstrated to associate with Rac1 and Rac3 in MDA-MB-231 breast carcinoma cells 
(Zhang et al., 2009). Knockdown of RhoGDI2 resulted in activation of Rac1 and 
translocation to the membrane, correlating with a decrease in tumor growth in xenograft 
models, and metastatic lung nodule formation of MDA-MB-231 cells in xenograft models. 
Mechanistically, knockdown of RhoGDI2 induced anoikis through Rac1-mediated activation 
of JNK and p38 MAPK pathways. In UMUC3 bladder carcinoma cells, RhoGDI2 was found 
to bind to Rac1 and inhibits its membrane targeting (Moissoglu et al., 2009). Mutants that 
increase or decrease affinity of RhoGDI2 for Rho GTPases nevertheless still blocked 
RhoGDI2-mediated Rac1 activation and suppress metastasis. Thus, it is thought that 
RhoGDI2 inhibits metastasis through Rac1, but through mechanisms distinct from impairing 
Rac1 membrane association. Another study demonstrated that Src binds and 
phosphorylates RhoGDI2 at residue Y153E that results in Rac1 plasma membrane 
localization in UMUC3 bladder cancer cells (Wu et al., 2009). A phosphomimetic RhoGDI2 
(Y153E) suppressed UMUC3 lung metastasis more than wild type RhoGDI2, suggesting 
that Src phosphorylation of RhoGDI2 regulates Rac1 membrane cycling and inhibits 
metastasis in bladder cancer.  
 
Altogether, RhoGDI2 has demonstrated opposing functions in different cancer cell types.  
RhoGDI2 can function as a positive (ovarian, breast, and gastric cancers) and negative 
(bladder cancer and Hodgkin’s lymphoma) regulator of cancer progression. This difference 
may be due to genetic diversity in different of cancer cell lines, types of cancers, or activity 
of different Rho GTPase family members in different cancers. 
 
1.7 Overview of nitric oxide. Nitric oxide (NO), a diatomic free radical naturally synthesized 
in the human body when L-arginine is converted to L-citrulline,(Moncada and Higgs, 1993) 
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regulates crucial bioregulatory functions in the cardiovascular, respiratory, gastrointestinal, 
genitourinary, and central and peripheral nervous systems (Marletta et al., 1990) These 
crucial bioregulatory functions have made this radical one of the most studied molecules in 
biomedical science (Tannenbaum et al., 1991). In mammals, the production of NO is 
catalyzed by one of three different isoforms of the NO synthase enzyme (NOS) (Marletta et 
al., 1990). Ranging in molecular weight from 130-160 kDa, these enzymes fall into two 
broad categories. Neuronal and endothelial NO synthases (nNOS and eNOS), represent 
constitutive enzymes, modulated by Ca2+ influxes. Conversely, inducible NO synthase, 
iNOS, is produced in many cell types, with especially high levels being formed as a 
response to inflammatory cytokines and host defense stimuli against pathogens (Saavedra 
and Keefer, 2002). 
 
The specific function of NO is regulated by both the location and amount of release. At 
nanomolar concentrations (generated by constitutive NOS), NO acts as a cell signaling 
molecule and interacts preferentially with target enzymes (e.g., guanylyl cyclase and 
cytochrome c oxidase) (Moncada and Higgs, 1993).  Interestingly, reactive oxygen species 
formation can activate RhoA and induce stress fiber formation (Aghajanian et al., 2009).  
When NO output is high (~mM), other enzymes become targets for NO’s action. For 
example, aconitase, NADH dehydrogenase and succinate dehydrogenase, non-heme 
metalloenzymes, and ribonucleotide reductase are all susceptible to inhibition by NO (Albina 
and Reichner, 1998).  Most of the actions of NO are ascribed to either its free radical nature 
or redox chemistry (Wink et al., 1998).  
 
Since both constitutive and inducible forms of NOS are present in tumors, NO likely impacts 
multiple stages of cancer development. The effects of NO are thus broad and complex, 
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spanning cytostatic processes, cellular transformation, formation of neoplastic legions, and 
regulation of various aspects of tumor biology including angiogenesis (Figure 1.8). Some 
consequences of NO production that suggest tumoricidal effects include inhibition of several 
classes of enzymes and iron metabolism proteins, cell apoptosis, and its effects in 
metastasis. Both isoforms of NOS have been detected in human breast tumors (Thomsen et 
al., 1995), cervical tumors (Thomsen et al., 1994), tumors associated with the central 
nervous system (Cobbs et al., 1995), colon (Jenkins et al., 1995; Radomski et al., 1991), 
and head and neck (Prazma et al., 1995) cancers. Properties of NO that may be beneficial 
in the treatment of cancer include its roles in the anti-pathogen and tumoricidal response of 
the immune system. It is well established that both monocytes and macrophages synthesize 
NO when stimulated by pathogens (Albina and Reichner, 1998; Lopez-Farre et al., 1998). 
Studies have also shown that reactive nitrogen species affect the expression and activity of 
proteins critical to the cell cycle and apoptosis, which are in turn influenced by mutations in 
DNA (Forrester et al., 1996; Kerwin, 1995; Messmer et al., 1994; Sandau et al., 1997).  
 
Several reports have indicated that NO produced by tumor cells may prevent infiltration of 
leukocytes and T-cell proliferation suggesting that in addition to increasing vascular 
permeability, NO down-regulates the expression of adhesion molecules important for 
inflammatory and immune cell adhesion to the vascular endothelium (Khan et al., 1996). In 
seminal experiments involving co-cultures of macrophages and lymphoma cells, Hibbs et al. 
and Stuehr et al. reported that NO generated from macrophages inhibited cellular respiration 
in cancer cells (Hibbs et al., 1987; Stuehr and Nathan, 1989). Subsequent reports 
demonstrated that NO derived from macrophages, natural killer cells, and endothelial cells 
was tumoricidal against many types of tumors (Cipone et al., 1994; Curley et al., 1993; 
Fukumura et al., 1996; Jiang et al., 1992; Klostergaard et al., 1991; Kurose et al., 1993; 
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Lepoivre et al., 1994; Leu et al., 1991; Li et al., 1991; Xiao et al., 1995; Yim et al., 1993; Yim 
et al., 1995). Since the formation of tumors occurs in several stages (e.g., initiation, 
promotion, and progression), NO may very well both accelerate tumor progression and 
conversely, in other settings, be tumoricidal.  
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Figure 1.8 Nitric oxide is important for many biological processes. As a result, many 
NO donor small molecule drugs have been developed as anti-coagulant, antibiotics, 
and anti-cancer agents. 
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1.8 Nitric oxide donors. The astounding pace of discovery on the physiological roles of NO 
(Adams et al., 1999; Keefer, 1998; Marletta et al., 1990; Saavedra and Keefer, 2002) and its 
role in tumor cell biology demands methods for generating NO in a controlled manner to 
facilitate improved understanding of its function in biological systems. Metal complexes, 
nitrosothiols, nitrosamines, and diazeniumdiolates have all been developed as effective NO 
donors (Wang et al., 2002).  The structural differences for each type have led to remarkably 
varied chemical reactivity and NO release kinetics.  The cytotoxic effects of these small 
molecule NO donors against tumor cells have been thoroughly studied (Gref et al.). Table 
1.3 illustrates the diversity of NO donor complexes explored as anti-cancer therapeutics and 
the broad spectrum of NO activity against various cancer cell lines. 
 
In a recent study, PABA/NO and related analogs were used to evaluate NO sensitivity using 
the NCI 51 human tumor cell line panel (Saavedra et al., 2006a).  This analysis identified the 
OVCAR-3 ovarian carcinoma cell line as among the four lines with the greatest sensitivity to 
NO-mediated inhibition of cell proliferation.  A previous study found that PABA/NO showed 
activity against mouse xenograft tumors of the human A2780 ovarian carcinoma cell line; 
this anti-tumor activity was comparable to that of cisplatin (Findlay et al., 2004), a 
chemotherapeutic drug used for ovarian cancer treatment.  Another study found that NO 
sensitized the A2780 and AD10 human ovarian carcinoma cell lines to Fas-mediated 
apoptosis (Garban and Bonavida, 1999).  This sensitivity of ovarian tumor cells to NO 
provided the rationale for focusing my studies of NO anti-tumor activity on ovarian cells. 
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Table 1.3 Representative examples of the tumoricidal effect of previously reported NO 
donors against a variety of cancer cell lines in vitro. 
Class of NO 
Donor Name Cancer Type Effect 
Metal Complex Sodium nitroprusside 
(SNP) 
Prostate 
(PC-3) 
antiproliferative and 
apoptotic effects through 
arrest of G1 phase of cell 
cycle 
    
Diazeniumdiolate DETA/NONOate Breast 
(MDA-MB-
231) 
induced cytostasis, 
arrested in the G1 phase of 
cell cycle 
    
 
 
PABA/NO Ovarian 
(A2780) 
in vitro/in vivo anticancer 
activity 
    
 MAHMA/NO Colon 
(HT-29) 
antiproliferative through 
inhibition of ornithine 
decarboxylase activity 
    
Nitrosothiol S-nitrosocaptopril  
(CapNO) 
Prostate 
(PC-3, CaP) 
enhanced the effect of 
Taxol induced cytotoxicity 
    
 S-nitroso-N-
acetylpenicillamine 
(SNAP) 
Oral 
(CAL27, 
HSC-2) 
cytotoxicity against cancer 
cells in vitro 
    
 Glyco-nitrosothiol 
(fructose-1-SNAP) 
Prostate 
(DU-145) 
cytotoxicity against cancer 
cells in vitro 
    
NO-NSAIDS NO-donating aspirin 
(NO-ASA) 
Lung, Colon, 
Breast, Skin 
inhibition of cell 
proliferation, induced 
apoptosis 
    
Nitrates glyceryl trinitrate  
(GTN) 
Breast 
(MCF-7) 
cytotoxicity against cancer 
cells in vitro 
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In the early 1960’s, Drago and Paulik first reported the formation of 1-amino-substituted 
diazen-1-ium-1,2-diolates or simply “diazeniumdiolates” from the reaction of NO with primary 
and secondary amines (Drago and Karstetter, 1961).  One equivalent of amine reacts with 
two equivalents of NO. The second equivalent of base is protonated, keeping the newly 
formed [N(O)NO]- group in a stable anionic form. While stable under ambient conditions, 
these compounds are capable of spontaneous (non-enzymatic) generation of NO in 
aqueous solution. The dissociation of diazeniumdiolates to NO proceeds with simple first 
order kinetics at pH 7.4, with half-lives ranging from 2 s to 20 h (Hrabie and Keefer, 2002). 
Keefer and coworkers have synthesized a wide variety of these adducts, diversifying the 
nucleophile residues that may encompass simple primary or secondary amines, polyamines, 
or secondary amino acids (Hrabie and Keefer, 2002; Hrabie et al., 1993; Maragos et al., 
1991). The ability of diazeniumdiolates to generate NO in physiological media makes their 
use ideal for probing many of NO’s bioregulatory effects in vivo, where the biological effects 
of these compounds correlated well with the NO release rates in phosphate buffers 
(Saavedra and Keefer, 2002). 
 
With respect to cancer, diazeniumdiolates and other small molecule NO donors have shown 
efficacy against prostate, colon, and human breast cancers by affecting drug efflux pumps, 
reversing multi-drug resistance, and down regulating proteins to induce cytostasis (Liu et al., 
2004a; Pervin et al., 2001; Riganti et al., 2005). Cells exposed to high fluxes of NO for short 
periods through short half-life NO donors exhibited increased sensitivity to NO. When 
longer-lasting NO donors were used the difference in tumor cell proliferation versus controls 
was not as great due to the lower NO flux. Petit et al. hypothesized that high concentrations 
of NO may be necessary to form reactive nitric oxide species which mediate cell death, 
while lower fluxes of NO may mediate cytostasis (via interaction with metal/tyrosyl radicals) 
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(Petit et al., 1996). The exact concentration of NO and the release longevity necessary to 
reduce tumor cell proliferation remain elusive.  
 
Since diazeniumdiolate complexes decompose spontaneously at physiological pH, their 
administration in vivo can present undesirable side effects at NO-sensitive sites throughout 
the body. A major challenge for the therapeutic application of NO thus involves targeting NO 
to a specific site so that it will affect only that target. By taking advantage of the chemical 
versatility of the diazeniumdiolate functionality, several strategies for preparing tissue 
selective donors drugs for cancer therapy have been proposed (Hrabie and Keefer, 2002). 
These strategies include stabilization of the diazeniumdiolates by covalently binding 
protecting groups to a terminal oxygen (Saavedra et al., 1992). The donor is thus referred to 
as being O2-protected.  This “prodrug” approach was developed by Saavedra et al. at the 
National Cancer Institute and theoretically permits the diazeniumdiolate to move freely 
throughout the circulatory system without spontaneous dissociation. For example, vinylated-
diazeniumdiolates store NO until delivered to the liver where epoxidation and hydrolysis of 
the diazeniumdiolate to NO occurred via catalysis by cytochrome P450 enzymes (Saavedra 
et al., 1992). In this respect, the diazeniumdiolate prodrug demonstrated liver selectivity, 
raising NO levels and thereby reducing the extent of programmed cell death in the liver. 
Further studies on O2-protected diazeniumdiolates have resulted in esterase sensitive NO 
donors that exhibited in vitro antileukemic activity and peptide diazeniumdiolates that were 
specifically metabolized by prostate specific antigen for the selective treatment of prostate 
cancer (Saavedra et al., 2000; Tang et al., 2001). Unfortunately, the small molecule 
diazeniumdiolates used in these studies characteristically have limited solubility, no barrier 
to renal clearance, lack a method for detection in vivo, and produce potentially carcinogenic 
byproducts that have circumvented their clinical application. 
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1.9 Nitric-oxide releasing nanoparticles as drug delivery agents. Clearly, continued 
research on fundamentally new approaches for generating and delivering NO is warranted. 
The primary obstacles impeding targeted delivery of diazeniumdiolate NO donors can be 
overcome through the development of NO-releasing nanoparticles that release controlled 
levels of NO. Based on their unique size-dependent physical and chemical properties, 
nanoparticles have the potential to revolutionize the field of medicine (Baraton, 2003; 
Feldheim and Foss, 2002; Fendler, 1198; Guiot, 1986; Rao et al., 2004). Indeed, nanoscale 
materials have been under development for a number of biological and medical applications 
including drug and gene delivery (Mah et al., 2000; Panatarotto et al., 2003), fluorescent 
biological labels (Bruchez et al., 1998; Chan and Nie, 1998; Wang et al., 2002), pathogen 
and protein detectors (Edelstein et al., 2000; Nam et al., 2003), DNA structure probes 
(Mahtab et al., 1995), tissue engineering (de la Isla et al., 2003; Ma et al., 2003), MRI 
contrast agents (Weissleder et al., 1990), and separation and purification of biological 
molecules and cells (Molday and MacKenzi, 1982). Nanoscale particles can be prepared 
using metal, inorganic, or organic precursors (Baraton, 2003; Feldheim and Foss, 2002; 
Fendler, 1198; Guiot, 1986; Rao et al., 2004). The core of the nanoparticle may be bare 
(i.e., uncoated) or have one or more outer layers that can be multifunctional.  
 
Mesoporous silica nanoparticles, bioceramic materials prepared from silicon dioxide, have 
been explored extensively as carrier systems for controlled delivery of drugs (Barbe et al., 
2004; Chang et al., 2005; Jain et al., 1998; Lai et al., 2003; Munoz et al., 2003), biocides 
(Aughenbaugh et al., 2001; Radin et al., 2001; Trewyn et al., 2004), genes (Roy et al., 
2005), and proteins (Han et al., 1999; Takahashi et al., 2001). The drug delivery potential of 
silica has received a great deal of attention because of their physical and chemical versatility 
(e.g., ability to form tunable mesoporous structures with controllable surface properties) and 
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non-toxic nature (Sayari and Hamoudi, 2001; Stein et al., 2000). The synthesis of hybrid 
inorganic-organic silica nanospheres modified with reactive organic groups (e.g., amines, 
carboxylates, thiols, olefins, halides, and epoxides) capable of further functionalization with 
deliverable target molecules (e.g., drugs) has been reported (Sayari and Hamoudi, 2001; 
Stein et al., 2000). A variety of silane-coupling agents with the aforementioned functional 
moieties are available for surface grafting (via free silanol groups) (Anwander et al., 1998). 
Antibodies, biopolymers, and molecular probes can be attached to the exterior of the 
nanoparticle to make it more biocompatible and/or allow for its optical detection via 
fluorescence. As the surface chemistry for functionalization is well developed, different 
ligands can be selectively attached to surface regions on the nanoparticle to diversify its 
utility (Figure 1.9). 
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Figure 1.9 Advantages of silica nanoparticle-based drug delivery over other NO 
storage-delivery systems. Silica nanoparticles increase the half-life of drugs in the 
blood stream through protecting them from degradation, are easy to sythesize and 
mass fabricate, physically and chemically versatile in that ligands can be attached to 
the surface of the particles and particle size can be modified, are non-toxic in nature 
and excreted in the urine, and exhibit enhanced permeability and retention compared 
to small molecule drugs because they are transported in cells through mechanisms 
independent of drug pumps. 
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1.10 Targeted delivery of nitric oxide. The goal of targeted drug delivery is to maximize 
the concentration of a drug in specific organs or tissues of interest, while minimizing 
systemic drug distribution and toxicity.  Useful drug delivery vehicles include liposomes (Lian 
and Ho, 2001), polymeric micelles (Torchilin, 2004), dendrimers (Gillies and Frechet, 2005), 
and several general classes of water soluble nanoparticles (Bala et al., 2004; Oishi et al., 
2005; Ulbrich et al., 2004; Yang et al., 2005). Such formulations have been used to 
successfully alter the pharmacokinetics, bio-distribution, and efficacy of many therapeutic 
compounds. With the proper targeting technology, these carrier systems have shown 
dramatic increases in the chemotherapeutic efficacy of anti-cancer drugs and are now 
approved for clinical use (Allen and Cullis, 2004; Brannon-Peppas and Blanchette, 2004). 
 
With respect to cancer, solid tumors possess patho-physiological characteristics like 
impaired lymphatic drainage, an elevated level of angiogenesis, and poor vascular 
architecture that are uncommon to normal tissue types (Maeda et al., 2000).  Carrier 
systems can be designed to deliver therapeutics to a specific site in vivo utilizing the unique 
properties of tumor cell biology. Passive targeting of macromolecular therapeutics is 
achieved via the enhanced permeability and retention (EPR) effect of tumor cell vasculature 
(Maeda et al., 2000). The key mechanism for the EPR effect is retention; substances <20-40 
kDa are returned to the blood, while larger, macromolecular carrier systems accumulate in 
the solid tumor tissue. Active targeting involves the attachment of a target-specific ligand to 
the carrier system exterior that will interact preferentially with tumor cell surface receptors 
over the receptors of healthy tissue (Mitra et al., 2004). Monoclonal antibodies targeting 
specific antigens on the tumor cell surface have been used to narrow the bio-distribution and 
increase the efficacy of many pharmaceutical formulations (Berman et al., 2004; Brannon-
Peppas and Blanchette, 2004; Dinauer et al., 2005; Wartlick et al., 2004). Ligand receptor 
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molecules, such as folic acid, have also been used as a successful method of active drug 
delivery, targeting the overexpression of folate receptors (FRs) on tumor cells (Lee and Low, 
1994; Stella et al., 2000; Sudimack and Lee, 2000). 
 
Several avenues of study are necessary to fully develop NO-releasing nanoparticles as 
potential cancer therapeutics, including the development of: 1) synthetic strategies to enable 
a wide range of NO release rates and payloads; 2) methods for chemically protecting the 
NO donor; and, 3) triggered release chemistry to initiate NO release once the nanoparticle 
reaches a target (Figure 1.10). The use and further development of chemistry to control the 
release of NO from nanoparticles via local environmental conditions and/or external signals 
is warranted. In this respect, the evolution of NO-releasing nanoparticles as more functional 
nanodevices may be realized. The concept of using controlled NO release to treat certain 
cancers is based on recent studies demonstrating the efficacy of small molecule NO donors 
for reducing tumor growth.  
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Figure 1.10 NO donors, diazeniumdiolates, have been coupled to silica nanoparticles 
to form a novel NO storage and delivery system. The advantages that the NO donor 
silica nanoparticles have when compared to the previously developed NO donor drugs 
are controlled therapeutic payload, targeted delivery to cancer verses normal cells 
through attaching ligands or varying the size of the particles, pH sensitive release of 
the NO such that NO is released when the nanoparticles reach an acidic intracellular 
environment, visual tracking of the particles through fluorescent tags, and physical 
movement of particles by magnetization. 
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Nitric Oxide-Releasing Silica Nanoparticles. Inorganic-organic hybrid silica nanoparticles 
were prepared via co-condensation of tetraalkoxysilane and aminoalkoxysilane with 
appropriate amounts of water, methanol or ethanol, and a catalyst [e.g., ammonia] to more 
homogeneously distribute the precursor throughout the ensuing nanoparticle (Lim and Stein, 
1999; Sanchez and Ribot, 1994). The amine functional groups in the silica structure were 
then converted to corresponding diazeniumdiolate NO donors via exposure to high 
pressures of NO (5 atm, 3 d), followed by addition of tettraethoxysilane (TEOS) (Figure 
1.11). Furthermore, control over the silane precursors and reaction/processing conditions 
allows for tremendous chemical flexibility in creating nanoparticles of diverse size and 
porosity, allowing greater NO storage and release properties (Figure 1.12).  
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Figure 1.11 Formation of NO-releasing silica nanoparticles. A) To form the N-
diazeniumdiolate NO donor moiety, aminoalkoxysilane solution was prepared 
by dissolution of an appropriate amount of an aminoalkoxysilane (i.e., AHAP3) 
in a mixture of ethanol, methanol, and sodium methoxide (NaOMe) base and 
then reacted with NO (5 atm) for 3 days. B) Next, tetraalkoxysilane (i.e., TEOS) 
was then mixed with different ratios of the N-diazeniumdiolate-modified 
aminoalkoxysilane (10−75 mol %, balance TEOS). Finally, the silane mixture 
was added to various solvent systems (e.g., 100% EtOH) in the presence of an 
ammonia catalyst (NH4OH) to form NO donor-modified silica nanoparticles via 
the sol−gel process (Shin et al., 2007; Shin and Schoenfisch, 2008). 
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Figure 1.12 NO release profiles of AHAP3 silica nanoparticles. A) Real time NO 
release profiles and B) total NO release amounts for diazeniumdiolate-modified C) 
AHAP3 silica nanoparticles at the indicated concentration (10, 25, 35, and 45 mol %; 
balance TEOS). B′) Inset plot represents expansion of graph B) from 0 to 2.0 h (Shin et 
al., 2007; Shin and Schoenfisch, 2008). 
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The synthesis of NO-releasing nanoparticles represents an important step toward the 
development of new NO delivery systems that bridge the gap between small molecule 
diazeniumdiolates and diazeniumdiolate-modified macroscopic polymers. The control over 
synthetic conditions allows for the preparation of nanoparticles with a range of NO-release 
properties. The size and stability of NO-releasing nanoparticles may also prove useful for a 
range of biomedical and pharmaceutical applications including potential cancer therapeutics.  
 
Enhanced Permeation and Retention Effect. Tumor tissue physiology possesses unique 
characteristics including increased levels of angiogenesis, impaired lymphatic drainage, and 
defective vascular architecture not found in normal cells (Maeda et al., 2000). The porous 
nature of the tumor vasculature provides a substantial supply of nutrients and oxygen for 
rapid growth. These structural properties result in intracellular accumulation of larger 
particles that typically do not have access to normal tissues. Also, the efflux pumps of 
diseased cells are also incapable of removing the larger particles resulting in increased 
retention (Maeda, 2004). This joint phenomenon is known as the enhanced permeation and 
retention (EPR) effect (Maeda, 2004; Maeda et al., 2000).  
 
The unusual structure of tumors has been the focus of many targeted drug delivery efforts. 
Plasmid DNA (Kawano et al., 2004), pirarubicin (Greish et al., 2005), and doxirubicin 
(Anderson, 2005; Greish et al., 2004; Muggia, 1999) have all been delivered as high 
molecular weight polymeric compositions and exhibit selective localization in cancerous 
tissue.  Nanoparticle drug carrier systems have also demonstrated similar efficacy against 
cancerous cells and show increased therapeutic efficacy in the treatment of solid tumors 
(Mitra et al., 2001; Son, 2003).  Anti-cancer therapeutics to be delivered by the EPR effect 
are formulated to approach a molecular weight range between 20-40 kDa (Maeda, 2004).  
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This range appears to be the average molecular weight of drug carriers that permeate the 
tumor vasculature, and tumor cells, yet remain too large to be excreted from the tumor cell, 
causing a concentrated amount of macromolecule inside the tumor cell. Typically, the 
nanoparticle compositions are synthesized to the desired molecular weight or PEG chains 
are covalently attached to the exterior to exceed the mass cutoff. The control over 
nanoparticle size prior to functionalization with NO donors allows for a tunable system for 
cell/tissue targeting via the EPR effect. Most importantly, macromolecules have been shown 
to accumulate in solid tumor tissue via the EPR effect for up to one hundred hours (Maeda 
et al., 2000). This incredibly long lifetime of potential NO-releasing silica nanoparticles inside 
the cell leads to a wide range of applicable NO release profiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
 
DEFINING THE ROLE, REGULATION AND MECHANISM OF RHO GUANINE 
NUCLEOTIDE DISSOCIATION INHIBITOR 2 (RHOGDI2) IN OVARIAN CARCINOMA 
CELLS 
 
2.1 Abstract 
Unlike the Ras oncogene proteins, which are mutationally activated in human cancers, Rho 
family GTPases are aberrantly deregulated by indirect mechanisms.  One such mechanism 
involves altered expression of Rho GTPase regulatory proteins such as Rho GDP 
dissociation inhibitor 2 (RhoGDI2), a negative regulator of Rho GTPases. We determined 
that RhoGDI2 protein expression is widely variable, with elevated levels in some ovarian 
carcinoma cell lines and increased expression in Ras-transformed ovarian epithelial cells. 
We therefore speculated that RhoGDI2 expression may promote tumor cell growth. 
Surprisingly, knockdown of RhoGDI2 in HeyA8 ovarian cancer cells resulted in increased 
Matrigel invasion in vitro and in tail-vein lung colony metastatic growth. To address a 
mechanism for RhoGDI2 suppression of invasion and metastasis, we also found that 
RhoGDI2 stably-associated preferentially with Rac1 but not with Cdc42, RhoA, or RhoC. 
Knockdown of RhoGDI2 resulted in decreased the level of GTP-bound active Rac1 but not 
RhoA or Cdc42 and translocation of Rac1 from the cytosol to membrane protrusions. In 
addition, there was a decrease in Rac-associated signaling pathways, the JNK and p38 
mitogen-activated protein kinase cascades. Our results suggest that RhoGDI2 
overexpression contributes to the metastatic phenotype of ovarian cancer cells, in part, by 
enhancing Rac-mediated signaling.  
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2.2 Introduction 
Rho GDP dissociation inhibitors (RhoGDIs) are generally considered as negative regulators 
of Rho GTPase activity by its ability to prevent nucleotide exchange, membrane association, 
and effector binding (Dovas and Couchman, 2005; Olofsson, 1999; Zhang, 2006).  RhoGDI 
binds and masks the C-terminal isoprenyl group of GTPases via an immunoglobulin-like 
domain and N-terminal regulatory portion of RhoGDI binds switch I and switch II regions of 
the Rho GTPases, thereby locking Rho GTPases in an inactive complex in the cytosol 
(Gosser et al., 1997; Hoffman et al., 2000; Keep et al., 1997).  However, RhoGDIs can also 
act as positive regulators via targeting Rho GTPases to subcellular membranes where they 
interact with different effectors or protect Rho GTPases from caspase degradation (Zhang, 
2006).  The Rho GTPases comprise a major branch of the Ras superfamily, with Rac1, 
Cdc42, and RhoA being the best characterized, are important regulators of actin 
cytoskeleton organization, cell cycle progression, and gene expression. Their aberrant 
function has been associated with human oncogenesis and other diseases (Horiuchi et al., 
2003; Qiu et al., 1995b; Yoshioka et al., 1999). 
  
There are three RhoGDI isoforms in humans: RhoGDI1 (also called GDI, GDIα), RhoGDI2 
(LyGDI/D4GDI/GDIβ), and RhoGDI3 (GDIγ). RhoGDI1 mRNA is ubiquitously expressed 
(Fukumoto et al., 1990), RhoGDI2 has hematopoietic tissue-specific expression particularly 
in B- and T-lymphocytes (Scherle et al., 1993), and RhoGDI3 is expressed in the brain, 
pancreas, lung, kidney, and testis (Adra et al., 1997).  RhoGDI1 and RhoGDI2 are cytosolic, 
whereas RhoGDI3 is vesicular membrane-anchored and exhibits specificity for interacting 
with RhoB and RhoG (Zalcman et al., 1996).  RhoGDI binding specificity to Rho GTPases is 
different for each isoform (DerMardirossian and Bokoch, 2005), has been best-characterized 
for RhoGDI1, and remain poorly characterized for RhoGDI2  (Ando et al., 1992; Berzat et 
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al., 2005; Faure and Dagher, 2001; Fiegen et al., 2002; Forget et al., 2002; Hiraoka et al., 
1992; Leonard et al., 1992; Matos et al., 2003; Michaelson et al., 2001; Regazzi et al., 1992; 
Ueda et al., 1990; Zalcman et al., 1996).  Knockout of RhoGDI1 or RhoGDI2 results in 
viable mice, perhaps due to the redundancy and compensation of isoforms in development.  
Knockout adult mice showed defects in kidney and reproductive organs (RhoGDI1) or 
immune responses (RhoGDI2) (Togawa et al., 1999; Yin et al., 1997).  Targeted knockdown 
of RhoGDI3 in the brain resulted in no abnormality in brain development or function in mice 
(Ferland et al., 2005).  Thus, the different RhoGDI isoforms may have distinct and 
overlapping biological functions that are not fully understood.  Finally, recent studies have 
identified protein kinases that phosphorylate RhoGDIs and regulate their ability to bind Rho 
GTPases. Also, novel RhoGDI-binding proteins have been identified that regulate the 
subcellular location of the RhoGDI-GTPase complex and caspase-mediate cleavage that 
create truncated, functionally-divergent variants of RhoGDIs (Krieser and Eastman, 1999; 
Na et al., 1996; Wu et al., 2009).  Hence, the regulation of RhoGDIs is complex and multi-
faceted and simple levels of expression may not be indicative of function. 
  
RhoGDIs are aberrantly expressed in human tumors and may be involved in oncogenesis.  
However, the associations are complex, with sometimes opposing roles and possible tumor 
type distinct functions.  Several genome-wide analyses have implicated altered RhoGDI 
expression in cancer progression and growth including ovarian, breast, and bladder cancer 
(Jones et al., 2002).  Theodorescu and colleagues reported that decreased RhoGDI2 
gene/protein expression was associated with a more invasive variant of the HRAS mutation 
positive T24 bladder cancer cell line (Gildea et al., 2002).  Ectopic restoration of RhoGDI2 
expression in the invasive T24 variant caused the decrease in tail vein lung metastasis 
invasion in mice.  Furthermore, they performed microarray analyses on an additional 105 
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primary tumors from lung, prostate, breast, colon and rectum, kidney, bladder and liver, and 
found that loss of RhoGDI2 RNA expression was associated with advanced tumor stage and 
grade.  These observations suggest that RhoGDI2 functions as an invasion and metastasis 
suppressor.  Furthermore, since RhoGDI2 is best known as a negative regulator of Rho 
GTPase function, these observations suggest a mechanism where loss of RhoGDI2-
mediated Rho activation may promote metastasis and invasion.  
 
In contrast to the bladder tumor line study, another study revealed RhoGDI2 expression in 
tumor but not benign breast tumor cell lines and the knockdown of RhoGDI2 in MDA-MB-
231 cells resulted in decreased motility and invasion (Zhang and Zhang, 2006).  
Mechanistically, D4-GDI was found to regulate breast cancer cell growth through a pathway 
that involves Rac GTPases and p38/JNK kinases (Zhang et al., 2009). In a third study with 
gastric carcinoma cell lines, RhoGDI2 protein was higher in gastric tumor tissues than 
normal gastric tissues and the expression level of RhoGDI2 protein correlated with lymph 
node metastasis (Cho et al., 2009). Ectopic overexpression of RhoGDI2 in SNU-484 and 
SNU-719 gastric carcinoma cells significantly increased invasiveness. Conversely, depletion 
of endogenous RhoGDI2 in SNU-638 and MKN-28 gastric carcinoma cells suppressed 
invasion in vitro. Forced expression of RhoGDI2 in these cells lines increased tumor growth, 
angiogenesis, and lung metastasis.  Thus, in contrast to breast carcinoma cells, RhoGDI2 
promotes rather than inhibits invasion and metastasis in breast and gastric tumor cell lines. 
 
Altered RhoGDI2 expression in ovarian cancer has also been reported. In one study, 
RhoGDI protein expression was identified via proteomic analyses to be overexpressed in 
invasive patient ovarian tumors (Jones et al., 2002), and hence, consistent with RhoGDI 
promotion of invasion and metastasis.  However, the specific isoform studied was not 
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determined in this study, and furthermore, no functional analyses were done.  In a gene 
array study, upregulation of RHOGDI2 transcription was associated with carcinoma when 
compared to benign adenoma tissue (Tapper et al., 2001). A third study found that RhoGDI2 
protein expression was elevated in the serum and tissue of cancerous relative to benign or 
normal ovarian tissue,  supporting the  potential of RhoGDI2 serum expression as a marker 
for the detection of ovarian cancer, in particular early stage ovarian cancer (Zhen et al.). In 
addition, in a microarray study to identify gene expression changes associated to paclitaxel 
resistance in ovarian cancers, RhoGDI2 overexpression correlated with resistance (Goto et 
al., 2006). Their immunohistochemical staining analyses of 22 serous ovarian cancer tissues 
from patients who received paclitaxel-based chemotherapy found that RhoGDI2 protein 
overexpression was observed more frequently in non-responders than in responders 
(p=0.004).  They concluded that RhoGDI expression may be a predictive marker of 
paclitaxel resistance not only in paclitaxel-resistant cell lines, but also in patient samples. 
 
When taken together, these studies suggest that RhoGDI2 overexpression is correlated with 
ovarian tumor progression.  However, no functional studies have been done to address a 
contribution of RhoGDI2 overexpression in ovarian cancer.  Therefore, we evaluated 
RhoGDI2 protein expression in transformed and tumor-derived ovarian cell lines and patient 
tumors.  We found that RhoGDI2 but not RhoGDI1 protein expression varied widely in a 
panel ovarian cancer cell lines and ovarian tumor tissue, and additionally, was elevated in 
Ras-transformed human ovarian surface epithelial cells, suggesting that RhoGDI2 
overexpressing may promote tumor growth.  Surprisingly, interfering RNA suppression of 
RhoGDI2 in the HeyA8 ovarian carcinoma cell line resulted in increased Matrigel invasion 
and increased lung colonization in a tail-vein lung metastatic assay. We also found that 
RhoGDI2 associates with Rac1 in ovarian cancer cells, but not with other Rho GTPases 
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tested (Cdc42, RhoA, and RhoC). Knockdown of RhoGDI2 results in decreased Rac1 
activity and the translocation of Rac1 from the cytosol to membrane protrusions.  In addition, 
knockdown of RhoGDI2 resulted in the decreased phosphorylation of the Rac-associated 
p38, and JNK, MAPK pathways, which were previously reported to be important for the 
metastatic ability of SKOV3 ovarian cancer cells (Hickson et al., 2006). Our results suggest 
that RhoGDI2 overexpression promotes Rac activation and signaling that may contribute to 
the metastatic phenotype of ovarian cancer cells. 
 
2.3 Results 
2.3.1 RhoGDI2 is differentially expressed in human ovarian carcinoma cells. Although 
previous studies suggested that RhoGDI2 protein overexpression correlated with ovarian 
tumor progression, a functional contribution to ovarian tumor growth has not been 
addressed.  Therefore, we first evaluated the expression of RhoGDI2 protein in human 
ovarian carcinoma cell lines derived from patients and the genetically engineered 
immortalized human ovarian surface epithelial (T29) cells and their transformed 
counterparts with active mutant Ras (T29 H-Ras, T29 K-Ras) by western blot analysis 
(Figure 2.1). We found widely variable levels of expression, with high RhoGDI2 levels seen 
in four ovarian carcinoma cells lines (HeyA8, OVCAR-3, OVCAR-4, and OVCAR-5).  We 
also found increased RhoGDI2 expression in Ras-transformed counterparts of immortalized 
human ovarian surface epithelial cells (T29 H-Ras and T29 K-Ras), suggesting that 
RhoGDI2 expression is elevated with tumor progression. In contrast, RhoGDI1 expression 
levels were equivalent for all cell lines. RhoGDI2 expression did not correlate with the 
invasive ability of cells in Matrigel assay or anchorage-independent growth measured in the 
soft agar assay (data not shown). Although, HeyA8 and OVCAR-5 cells expressed the 
highest levels of RhoGDI2 and were the most invasive compared to the entire panel of cell 
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lines. These data suggest RhoGDI2 expression may be associated with the transformed and 
tumorigenic growth of ovarian cancer cells.  
 
2.3.2 Stable knockdown of RhoGDI2 in HeyA8 ovarian carcinoma cells. To test if 
RhoGDI2 overexpression contributes to the growth and invasive phenotype of ovarian 
cancer cells, we selected to study HeyA8 cells, which exhibited very high levels of RhoGDI2 
protein expression.  HeyA8 cells were stably infected with either control off-target shRNA 
(GFP) or two independent shRNAs directed against RhoGDI2 (designated RhoGDI2 I and 
RhoGDI II). Three days after infection, cells were selected with puromycin to establish mass 
populations of cells with RhoGDI2 suppression, and we performed blot analyses to verify 
suppression of expression of RhoGDI1 and RhoGDI2. The GFP shRNA off-target control 
construct had no effect on RhoGDI2 expression, whereas both RhoGDI2 I and RhoGDI2 II 
shRNA-expressing cells showed greatly decreased steady-state expression levels of at least 
90% (Figure 2.2A). In addition, RhoGDI1 expression levels did not change after knockdown 
of RhoGDI2, indicating no compensatory increase.  
 
2.3.3. Stable suppression of RhoGDI2 expression enhances HeyA8 ovarian carcinoma 
cell Matrigel invasion and anchorage-independent growth. Suppression of RhoGDI2 
expression did not cause a detectable alteration in morphology nor growth rate on plastic.  
However, when the cells were evaluated in the Matrigel invasion assay, HeyA8 RhoGDI2 
knockdown cells displayed a significant increase in invasion when compared to control cells 
(Figure 2.2B). Additionally, RhoGDI2 suppression in HeyA8 cells significantly increased 
colony formation frequency in soft agar (anchorage-independent growth) when compared to 
control cells (Figure 2.2C and D).  Thus, unexpectedly, although RhoGDI2 expression was 
 
 
 
 67 
elevated in HeyA8 cells, these results support a tumor and invasion suppressor function of 
RhoGDI2 in ovarian tumor cells. 
 
2.3.4 Loss of RhoGDI2 increases metastatic ability of HeyA8 ovarian carcinoma cells 
in the tail-vein lung colonization assay.   To determine whether down-regulation of 
RhoGDI2 altered the metastastatic growth properties of HeyA8 cells, cells were injected 
intravenously into the tail veins of nude mice and lung colonization and tumor formation 
were measured. In this experimental metastasis assay, we observed a significant increase 
in the number of lung nodules in mice injected with HeyA8 RhoGDI2 knockdown cells 
compared to control cells (Figure 2.3). Metastatic nodules were not observed in other 
organs in the mice. These results demonstrate that targeted disruption of RhoGDI2 
increased the experimental metastasis of HeyA8 cells in nude mice.  
 
2.3.5 RhoGDI2 binds primarily with the Rho GTPase, Rac1, and positively regulates its 
activity in ovarian carcinoma cells. We next evaluated a mechanism by which RhoGDI2 
may control invasion.  Since the best characterized activity of RhoGDI2 is to interact with 
and prevent RhoA, Rac1 and Cdc42 membrane association and/or GEF-mediated 
activation, we determined which Rho GTPase associates with RhoGDI2 in HeyA8 cells. 
Whole cell extracts from HeyA8 cells were incubated with either GST alone, GST-RhoGDI2, 
or GST-RhoGDI1 beads and then subjected to Western blot analysis probing for the 
classically studied Rho GTPases, Rac1, Cdc42, and RhoA/C (Figure 2.4A). We found that 
all three Rho GTPases were associated with RhoGDI, only Rac1 was associated with 
RhoGDI2.  Next, to determine if knockdown of RhoGDI2 expression changed the activity 
level of Rac1, Cdc42, or RhoA/C, cell lysates were subjected to pull down analyses to 
measure the level of active GTP-bound GTPases in cells.  Cell lysates from control and 
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RhoGDI2 silenced cells were incubated with GST-Rhotekin-RBD, GST-PAK-RBD, or control 
GST-beads alone and subjected to SDS-PAGE followed by western blot analysis to detect 
Rac1, Cdc42, and RhoA/C (Figure 2.4A). Rac1-GTP expression levels decreased after 
knockdown of RhoGDI2, whereas the levels of GTP-bound RhoA/C or Cdc42 did not 
change (Figure 2.4B). Total Rac1, RhoA and Cdc42 expression levels were not changed 
between control and RhoGDI2 knockdown cells (Figure 2.4C). Next, fluorescent microscope 
was performed to detect if Rac1 subcellular and membrane localization changed upon 
knockdown of RhoGDI2. Knockdown of RhoGDI2 was associated with an increase in Rac1 
localized membrane protrusions (Figure 2.4D).  Thus, suppression of RhoGDI2 expression 
was associated with a reduction in activity and altered subcellular localization of Rac1. 
 
Activated Rac1 has been shown to stimulate activation of the p38 and JNK MAPK 
cascades.  Since we found that Rac1 activity and localization was altered on RhoGDI2 
suppression, we determined if Rac-associated signaling was altered. Western blot analysis 
was done to monitor the levels of phosphorylated and activated MKK3/MKK6, which act 
upstream of p38 or JNK (Figure 2.4E). We found that knockdown of RhoGDI2 decreased 
phospho-MKK3/6, phospho-JNK, and phospho-p38 levels. This result is consistent with 
RhoGDI2 suppression-associated loss of Rac1 activation. 
 
2.4 Discussion 
Although previous studies observed increased RhoGDI2 expression with ovarian tumor 
progression, no contribution of RhoGDI2 expression was addressed in these studies.  When 
evaluated in other cancer types, tumor type differences were seen, where RhoGDI2 
displayed properties of a invasion and metastasis suppression in some tumor cells 
(bladder), yet exhibited properties of an oncoprotein in other tumor types (breast and gastric 
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carcinoma cell lines). Although our studies of Ras-transformed human ovarian surface 
epithelial cells suggest that RhoGDI2 is overexpressed in tumor development, our shRNA 
suppression studies in the HeyA8 ovarian carcinoma cell line showed that suppression of 
RhoGDI2 expression was associated with increased anchorage-independent growth, 
increased Matrigel invasion and increased lung colony metastatic tumor formation.  Finally, 
we found that RhoGDI2 preferentially associated with Rac1 and not RhoA or Cdc42 and that 
suppression of RhoGDI2 expression was associated with reduced Rac1 activation and Rac-
associated signaling activities.  Thus, we suggest that RhoGDI2 expression may be a good 
prognostic marker for ovarian cancer. 
 
Altered RhoGDI2 expression has been observed for a variety of cancer types including 
ovarian cancers.  For ovarian cancer, several studies suggest that RhoGDI2 overexpression 
is associated with tumor progression, with increased expression in cancerous tissue.  In our 
analyses of a panel of ovarian tumor cell lines, we found widely variable levels, with very 
high levels in a subset of cell lines.  Since we found that RhoGDI2 expression levels were 
increased in Ras-transformation of immortalized human ovarian surface epithelial cells, we 
speculated that RhoGDI2 may function as positive-mediator of ovarian tumor cell growth.  
Therefore, we were surprised when we found that shRNA suppression of RhoGDI2 
expression enhanced growth, invasion and metastasis of the HeyA8 tumor cell line.  Thus, 
similar to bladder cancer, RhoGDI2 may function as an invasion and metastasis suppressor.  
One caveat to our studies is that our observations were made on only one cell line.  Further 
study with other cell lines will be needed to determine if this RhoGDI2 function can be 
generalized to other ovarian tumor cells. 
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The mechanism by which RhoGDI2 regulates cancer cell invasion is unclear, although 
previous studies have implicated the involvement of Rac1. For example, RhoGDI2 was 
demonstrated to bind Rac1 in the MDA-MB-231 breast cancer cell line and knockdown of 
RhoGDI2 resulted in Rac1 activation, translocation to the membrane, and correlated with a 
decrease in xenograft tumor growth, and metastatic lung nodule formation in nude mice 
(Zhang et al., 2009). In addition, knockdown of RhoGDI2 induced anoikis through Rac1-
mediated activation of JNK and p38 kinase pathways. Conversely, Rac1 blockade inhibited 
p38/JNK kinase activities and spontaneous anoikis of RhoGDI2 knockdown cells. Another 
study demonstrated that in bladder cancer cells (UMUC3) RhoGDI2 binds, increases 
activity, and blocks membrane targeting of Rac1 (Moissoglu et al., 2009). Mutations that 
alter the affinity of RhoGDI2 for Rho GTPases prevented RhoGDI2-mediated Rac1 
activation and suppressed metastatic lung nodule formation in nude mice. In our studies, we 
also found that RhoGDI2 function was linked to Rac1 and not to RhoA or Cdc42 regulation.  
In contrast to RhoGDI1, RhoGDI2 associated with Rac1 but not RhoA or Cdc42.  Consistent 
with this selective Rho GTPase association, shRNA suppression of RhoGDI2 expression 
was associated with altered subcellular localization and reduced Rac-GTP levels.  These 
results suggest that the loss of RhoGDI2 binding promoted Rac1 sensitivity to RacGAPs, or 
decreased sensitivity to RacGEFs, leading to loss of Rac1 activity and signaling.  Since p38 
and JNK activation has been shown previously to inhibit ovarian cancer metastasis (Hickson 
et al., 2006), this suggests that the reduced activity of these Rac-associated signaling 
pathways contributes to the enhanced growth properties of RhoGDI2-depleted HeyA8 cells.   
 
In summary, our observations support the role of RhoGDI2 as an invasion and metastasis 
suppressor in ovarian cancer.  Further analyses of RhoGDI2 expression in primary and 
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metastatic ovarian tumors will be needed to support this possibility, where we speculate that 
RhoGDI2 expression will be decreased in metastatic ovarian cancer.   
 
2.5 Material and methods 
2.5.1 Cell lines, drugs, and antibodies 
OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SKOV-3 ovarian cancer cells were 
provided by Dr. R. Camalier of Division of Cancer Treatment and Diagnosis Tumor 
Repository at NCI (Frederick, MD). A2780 ovarian cancer cell line was provided by Dr. T. 
Fojo of Cancer Therapeutics Branch at NCI (Bethesda, MD). The HeyA8 ovarian cancer cell 
line was provided by Dr. G. Mills at MD Anderson Cancer Center (Houston, TX). T29, T29 
H-Ras, and T29 K-Ras ovarian cell lines were established and characterized previously (Liu 
et al., 2004b). The phospho-specific and total JNK, MKK3/6, MLC, p38 antibodies were from 
Cell Signaling (Boston, MA). ERK1/2, RhoGDI1, RhoGDI2 (Ly-GDI (C20)), RhoA/C (119), 
and RhoB (119) antibodies for western blot analyses (Stevens et al., 2008) were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Rac1 antibody was purchased from 
Upstate (Billerica, MA) and Cdc42 antibody from BD Transduction (Franklin Lakes, NJ). 
Puromycin was purchase from Sigma (St. Louis, MO). 
 
2.5.2 Plasmids and creation of stable cell lines.  
Infectious retroviruses were generated by transfection of pSuper-Retro-Puro shRNA 
plasmids directed against either GFP (off-target control) or the RhoGDI2 sequences 5’-
GCGAGGCACGTACCACA-3’ (designated RhoGDI2 I) and 5’-
GGCCTGAAATACGTTCAGC-3’ (designated RhoGDI2 II) into the pCL-10A1 packaging 
plasmid. Infection virus supernatants were used for stable infection of HeyA8 ovarian cancer 
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cells and thus yielded mass populations of puromycin-resistant cells, as previously 
described.  
 
2.5.3 Metastasis assay by tail-vein injection.  
Female athymic nude mice (4-6 weeks old) were injected via lateral tail vein, one million 
cells trypsinized and suspended in PBS. After 6 weeks, the mice were sacrificed by carbon 
dioxide exposure, and the lungs were removed and kept in Bouin’s fixative. Tumor nodules 
on the lung surface appeared white and were counted and measured under the dissecting 
microscope. 
 
2.5.4 Western blot analysis.  
Western blotting was performed as previously described. Briefly, cells were washed with 
PBS, lysed in RIPA lysis buffer [50mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.1% 
SDS, 0.5% sodium deoxycholate and supplemented with Complete Protease Inhibitor 
Cocktail tablets (Roche) plus PMSF]. Samples containing 20 µg of protein in an SDS 
standard loading buffer were electrophoresed in a 12% SDS/PAGE and transferred to 
Immobilon membranes. Membranes were incubated with I-Block blocking buffer (Tropix, 
Bedford, MA) with 0.1% Tween 20. The blot was incubated with specific primary antibodies 
followed by anti-mouse, rabbit, or goat IgG–horseradish-peroxidase-conjugated secondary 
antibody (Amersham Biosciences). Membranes were then incubated in SuperSignal West 
Dura Extended Duration substrate (Pierce) and the signal developed on HyBlot CL 
autoradiography film (Denville Scientific). 
 
2.5.5 Pull-down assay.  
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Pulldown analyses were done as previously described (Boulter et al., In press). Briefly, the 
GTP-bound Rho GTPase levels in lysates were measured using a glutathione S-transferase 
(GST) fusion protein containing the isolated RBD derived from the RhoA/C effector, 
Rhotekin (GST-Rhotekin-RBD provided by K. Burridge, UNC, Chapel Hill, NC) or Rac and 
Cdc42 effector, the PAK1 serine/threonine kinase, GST-PAK-RBD (Cytoskeleton Inc., 
Denver, CO). Immunoblot analyses were performed using antibodies against Rac1, Cdc42, 
and RhoA/C for detection of GTP-bound Rho GTPases and for total cell lysate protein 
levels. 
 
2.5.6 In vitro binding of RhoGDIs to Rho GTPases.  
Cells were lysed with 50 mm Tris, pH 7.5, 150 mm NaCl, 1 mm dithiothreitol, 5 mm MgCl2, 
0.5% Triton X-100, and a protease inhibitor mixture tablet (Invitrogen). The lysates were 
cleared by centrifugation at 12,000 rpm for 10 min at 4°C, and 200 µg of total protein 
extracts were used per condition. 15 µg of either bacterially expressed GST, GST-RhoGDI1 
or GST-RhoGDI2 (E. Boulter, UNC, Chapel Hill, NC), immobilized on glutathione 
Sepharose™ 4B beads (Amersham Biosciences), was incubated with lysates on a rotator at 
4°C for 1 h. The beads were washed three time with lysis buffer, and the affinity-precipitated 
proteins were eluted in protein sample buffer and analyzed by SDS-PAGE and western 
blotting with either RhoGDI1 or RhoGDI2 specific antibodies. 
  
2.5.7 Soft agar assy.  
Soft agar assays were performed by seeding single cell suspensions in growth medium at 
10,000 cells/well supplemented with 0.4% bacto agar. Colonies formed within three weeks 
and were stained with MTT, then scanned on a Canon 9900F flat bed scanner (Canon, Lake 
Success, NY) and counted using Image J software (NIH, Bethesda, MD).  
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2.5.8 Matrigel invasion assay.  
In vitro invasion activity was measured using BioCoat Matrigel invasion chambers (BD 
Bioscience). HeyA8 cells were dissociated with TrypLE Express (Invitrogen), and 20,000 
cells resuspended in serum-free media were seeded into the upper chamber. Growth 
medium supplemented with 10% FCS (chemoattractant) was added to the well beneath the 
chamber. After 20 h at 37°C, cells on the upper surface of the membranes were removed by 
scraping with a cotton swab, and those on the lower surface were fixed, stained with 
hematoxylin and eosin (H&E), and quantified.   
  
2.5.9 Confocal fluorescence microscopy.  
Cells were plated on glass coverslips coated with 0.01% gelatin. Cells were fixed in 4% 
paraformaldehyde, permeabilized in 0.2% Triton X-100, blocked in 0.2% bovine serum 
albumin (BSA), and incubated in primary [Rac1 (1:500 dilution)] followed by secondary 
Alexa-594 antibodies. Cells were mounted on coverslips with FluorSave (Calbiochem; 
Gibbstown, NJ) and imaged with a Zeiss Laser Scanning Microscope (LSM 510, Germany).  
  
2.6.0 Statistical analysis.   
Statistical analysis was performed by Student’s t-test using Microsoft Excel Office 2008 and 
p-values of <0.05 were considered statistically significant.  
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Figure 2.1 Variable levels of RhoGDI2 but not RhoGDI1 protein expression in human 
ovarian cell lines. Cell lysates were subjected to immunoblotting analysis using 
antibodies specific for RhoGDI1, RhoGDI2, or the loading control (ERK). HeyA8 and 
OVCAR-5 cell lines are K-Ras mutation positive (12D and 12V). T29 is a 
nontransformed, immortalized human ovarian surface epithelial cell line that was then 
stably-transfected with active mutant H-Ras(12V) or K-Ras(12V), and designated T29 
H-Ras and T29 K-Ras, respectively. These results are representative of three 
independent experiments. 
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Figure 2.2 Stable suppression of RhoGDI2 in HeyA8 cells increases Matrigel invasion 
and anchorage-independent growth in soft agar. A) HeyA8 cells were stably infected 
with either control GFP shRNA or two independent shRNA sequences against human 
RhoGDI2 (designated RhoGDI2 I and RhoGDI2 II) followed by selection with 
puromycin. Puromycin-resistant cells were analyzed for RhoGDI1, RhoGDI2, and the 
total protein loading control, ERK1/2. B) Effect of knockdown of RhoGDI2 on the 
Matrigel invasive ability of HeyA8 cells. 20,000 cells were plated in Matrigel chamber 
and assayed after 24 h. Invasion of RhoGDI2 knockdown cells were markedly 
increased compared with that of control GFP cells (*P<0.001). C) The soft agar assay 
was performed to evaluate the ability of knockdown of RhoGDI2 to inhibit anchorage-
independent growth of HeyA8 cells. Cells were suspended in soft agar supplemented 
with growth medium and colonies formed within three weeks. Colonies were stained 
with MTT and quantified using Image J software and D) scanned images of soft agar 
plates are shown. RhoGDI2 knockdown cells demonstrated a significant increase in 
colony forming ability compared to control GFP cells (*P<0.05). These results are 
representative of three independent experiments. 
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Figure 2.3 Knockdown of RhoGDI2 in HeyA8 cells increases lung colonization. A) The 
tail-vein lung metastasis assay was performed to determine if knockdown of RhoGDI2 
in HeyA8 ovarian cancer cells affects tumor cell lung colonization. 1.5 x 106 cells of 
either RhoGDI2 knockdown (I and II) or control (GFP) cells were injected into the 
mouse tail-vein. After 6 weeks, mice were euthanized. Lungs were inflated, fixed, 
stained with Bouin’s fixative, and then destained with ethanol. B) Size and number of 
lung tumors were measured. RhoGDI2 knockdown cells demonstrated a significant 
increase in lung colonization compared to control GFP cells (*P<0.05 and *P<0.001). 
These results are representative of two independent experiments. 
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Figure 2.4 RhoGDI2 binds and regulates Rac1 activity, localization, and downstream 
signaling in HeyA8 cells. A) HeyA8 cell lysates were incubated with either GST alone, 
GST-GDI1, or GST-GDI2 beads and then subjected to western blot analysis probing 
for RhoA/C, Rac1, or Cdc42. B) To determine if knockdown of RhoGDI2 affects levels 
of GTP-bound Rho GTPases, pull down analyses were done on cell lysates GST-PAK-
RBD and then subjected to western blot analysis. C) Western blot analysis of total 
input lysates were used for pull downs. D) Confocal microscopy analysis was 
performed with HeyA8 GFP, RhoGDI2 I, and RhoGDI2 II shRNA cell lines staining for 
Rac1, phalloidin, Rac1 and phalloidin, or secondary antibody alone (control). E) 
Western blot analysis was performed with HeyA8 cells stably infected with shRNA 
targeting GFP or RhoGDI2 and then examined for RhoGDI2, pMMK3/6, MKK6, pJNK, 
JNK, pp38, p38, pMLC, MLC, pERK, RhoGDI2. Blot analysis for total ERK1/2 was 
done to verify equivalent loading of total cellular protein. These results are 
representative of three independent experiments. 
 
 
CHAPTER III 
 
NITRIC OXIDE-RELEASING NANOPARTICLES AS A POTENTIAL TARGETED 
THERAPY FOR OVARIAN CARCINOMA 
 
This work was published in Molecular Pharmaceutics 7, 775-785 (2010). 
 
 
3.1 Abstract 
 
Although the potent anti-tumor activity of NO supports its promise as an anti-neoplastic 
agent, effective and selective delivery and action on tumor and not normal cells remains a 
limiting factor.  Nanoparticle-based delivery of NO has been considered as one approach to 
overcome these limitations. Therefore, we determined the utility of NO delivery using silica 
nanoparticles and evaluated their anti-tumor efficacy against human ovarian tumor and 
nontumor cells. The NO-releasing nanoparticles exhibited enhanced growth inhibition of 
ovarian tumor cells when compared to both control nanoparticles and a previously reported 
small molecule NO donor, PYRRO/NO. In addition, the NO-releasing nanoparticles showed 
greater inhibition of the anchorage-independent growth of tumor-derived and Ras-
transformed ovarian cells. Confocal microscopy analysis revealed that fluorescently-labeled 
NO-releasing nanoparticles entered the cytosol of the cell and localized to late endosomes 
and lysosomes. Furthermore, we observed a nanoparticle size dependency on efficacy 
against normal versus transformed ovarian cells. Our study provides the first application of 
nanoparticle-derived NO as an antitumor therapy and supports the merit for future studies 
examining nanoparticle formulation for in vivo applications. 
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3.2 Introduction 
Nanotechnology has benefited a number of biomedical areas including drug delivery and 
magnetic resonance imaging contrast agents (Bruchez et al., 1998; Mahtab et al., 1995; 
Nam et al., 2003; Reddy, 2005; Weissleder et al., 1990). The use of nanostructured 
materials (e.g., nanoparticles) as drug delivery systems has begun to impact medicine due 
to beneficial size-dependent physical and chemical properties (Zhang et al., 2008).  Due to 
their non-toxic nature and ability to form structures of tunable porosity, size, and surface 
functionalities, organically-modified silica nanoparticles have been explored as a carrier 
system for the controlled delivery of drugs, biocides, genes, and proteins (Barbe et al., 2004; 
Brunner et al., 2006; Sayari and Hamoudi, 2001; Stein et al., 2000). A limitation of cancer 
chemotherapy is the narrow therapeutic index of the majority of anti-neoplastic agents, with 
effective delivery to tumor cells, tumor cell resistance and normal cell toxicity the major 
concerns. The targeting capabilities available with nanoparticle-based drug delivery provide 
an attractive approach to overcome these limitations with improved site-specific delivery to 
the tumor (Byrne et al., 2008; Cho et al., 2008). 
 
NO, a free radical bioregulator endogenously synthesized in the body, impacts multiple 
stages of tumor development, spanning cytostatic processes, cellular transformation, and 
formation of neoplastic lesions (Bonavida et al., 2006; Huerta et al., 2008b; Miller and 
Megson, 2007). Recent reports have highlighted the consequences of NO production on 
tumor biology including the inhibition of several classes of enzymes and iron metabolism 
proteins, cell apoptosis, and alternation of metastasis (Albina and Reichner, 1998; 
Fukumura et al., 2006). Studies have shown that reactive nitrogen oxide species (e.g., NO2, 
NO2-, ONOO-, and N2O3) derived from NO impact the expression and activity of proteins 
critical to the cell cycle and apoptosis (Albina and Reichner, 1998; Lo and Hung, 2006). 
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To further understand the anti-cancer efficacy of NO, several classes of small molecule NO 
donors (e.g., NO-metal complexes, nitrosothiols, organic nitrites/nitrates, and 
diazeniumdiolates) have been developed and evaluated with respect to NO storage/release 
and efficacy against tumor cells (Adami et al., 1998; Huerta et al., 2008a; Jia et al., 2003; 
Mimeault et al., 2005; Pervin et al., 2001). For example, small molecule diazeniumdiolate 
NO donors have been used to demonstrate the efficacy of NO as a potent antitumor agent 
against ovarian cancer cells, the leading cause of death from gynecologic malignancies  
(Saavedra et al., 2006b).  Indeed, O2-{2,4-dinitro-5-(4 -(N-methylamino)- 
benzoyloxy]phenyl})]-1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate (PABA/NO) delayed 
human ovarian cancer tumor xenograft growth with potency similar to that of cisplatin, the 
mainstay of treatment for ovarian cancer (Saavedra et al., 2006b). Another study 
demonstrated the efficacy of NCX-4016, a derivative of nitroaspirin, against cisplatin-
resistant human ovarian cancer cells and xenograft tumors (Bratasz et al., 2006). Although 
small molecule NO donors have shown efficacy against tumors, their usefulness as 
anticancer agents is hindered clinically due to possible normal cell toxicity of the NO donor 
drug byproduct and the inability to target delivery of the drug selectively to cancer cells. 
 
In this study, we have engineered NO-releasing silica nanoparticles as a therapeutic tool to 
determine if this would improve NO delivery to human ovarian cancer cells and have 
decreased cytotoxicity toward normal cells.  We recently reported the synthesis of NO 
donor-modified silica nanoparticles that possess remarkably tunable nanoparticle size and 
NO storage/release properties (Shin et al., 2007; Shin and Schoenfisch, 2008). This delivery 
system allows us to control the therapeutic payload and visualize the nanoparticles through 
fluorescent tags. We compared the cytotoxicity of nanoparticle-derived NO to NO released 
from a small molecule NO donor (PYRRO/NO) and found increased anti-tumor activity of the 
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nanoparticle-derived NO against ovarian tumor or transformed cell lines.  Size-dependency 
studies suggest that selective cytotoxicity against tumor cells was enhanced by modulation 
of nanoparticle size.  Our observations support the effectiveness of NO-releasing 
nanoparticles against ovarian cancer cells and merit future studies for further developing 
these materials for evaluation of anti-tumor activity in mouse models of ovarian cancer. 
 
3.3 Results 
3.3.1 Synthesis and Characterization of NO-Releasing Silica Nanoparticles. The 
structure and concentration of the N-diazeniumdiolate-modified silane precursors as well as 
the solvent employed during the sol–gel polymerization was found to influence nanoparticle 
size and NO release properties (Table 3.1). Adjusting the type and concentration of NO 
donor-modified silane derivatives (i.e., N-diazeniumdiolated AHAP3 or MAP3) lead to 
nanoparticles ranging in diameter from 90 to 161 nm. As we observed previously, the 
diameter of the nanoparticle decreased with increasing N-diazeniumdiolated silane 
concentration.(Polizzi et al., 2007) Other related studies have shown that the chain-length of 
the alcohol solvent affects the kinetics and degree of hydrolysis and condensation, 
ultimately resulting in the formation of nanoparticles of different diameters.(Hong et al., 
2004) In our analyses, we determined that the diameter of 75 mol% N-diazeniumdiolated 
MAP3 (balance TEOS) silica nanoparticles increased from 90 ± 10 nm for the silica 
prepared in 100% EtOH to 350 ± 50 when prepared in 50:50% EtOH:PrOH. 
 
The NO storage and release properties of N-diazeniumdiolate-modified silica nanoparticles 
analyzed under physiological conditions (in PBS at pH 7.4 and 37 °C) are summarized in 
Table 1. The NO release profiles and total NO released from N-diazeniumdiolate-modified 
silica nanocomposites with different concentrations of MAP3 precursors (i.e., 45 to 75 mol%, 
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balance TEOS) are shown in Figs. 1A and 1B. As expected, the initial NO release was 
characterized by a bolus of NO ranging from 3.3 x 104 to 10.3 x 104 ppb/mg depending on 
the MAP3 concentration. In addition, increasing the mol% of MAP3 from 45 to 75 mol% led 
to a corresponding increase in total NO release (t[NO]), ranging from 1.59 to 7.35 µmol/mg. 
Increasing nanoparticle diameter from 90 nm to 350 nm resulted in an increase in t[NO] from 
7.35 to 12.52 µmol/mg.. The maximum concentration of NO release ([NO]m) for 45 mol% 
MAP3 was larger than that for AHAP3 of the same mol% (3.30 x 104 and 2.17 x 104 ppg/mg, 
respectively), while the total NO release was lower (1.59 µmol/mg and 3.77 µmol/mg). 
 
3.3.2 Cytotoxicity of NO Donor Silica Nanoparticles Against Ovarian Carcinoma Cells. 
To study the tumoricidal potential of NO donor silica, we first evaluated the cytotoxicity of 
control and N-diazeniumdiolate-modified silica nanoparticles on the A2780 human ovarian 
carcinoma cell line. The MTT viability assay was employed to determine the relative 
sensitivities of A2780 cells to growth inhibition by each nanoparticle treatment. The 
sensitivity (expressed as minus the logarithm base 10 of the 50% growth inhibitory 
concentration (IC50)) of the small molecule NO donor (PYRRO/NO) was 2 mM (Fig. 2A). We 
found that the NO-releasing silica (AHAP3/NO and MAP3/NO) exhibited greater cytotoxicity 
against A2780 cells than when treated with similar doses of NO from PYRRO/NO (Figs. 2B 
and 2C).  A2780 cells were treated with varying doses of control and NO-releasing AHAP3 
silica (13 – 1000 µg/mL) and viability was nearly completely inhibited at a dose of 500 
µg/mL. Even the lowest concentration of NO-releasing silica nanoparticles tested proved 
cytotoxic against cancer cells, potentially resulting from a small population of the 
heterogeneous cancer cells with higher sensitivity to the nanoparticles. The concentrations 
of NO released indicated in Fig. 2 are theoretical concentrations calculated from those 
values listed in Table 1 based on the dose of PYRRO/NO, AHAP3/NO particle, or MAP3/NO 
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particle.  The actual concentration of NO available during the MTT assay, which was 
performed in open-air conditions, is expected to be slightly lower than the theoretical 
concentration determined from the analysis in a sealed vessel. 
 
We also observed that control AHAP3 silica nanoparticles (i.e., non-diazeniumdiolate 
modified) exhibited cytotoxic effects against the tumor cells (IC50 = 120 µg/mL), albeit less 
than that of their NO-releasing counterparts. We attributed this cytotoxicity of the AHAP3 
controls to the primary amines available on the surface of the silica structures. To reduce 
the cytotoxicity of control and NO-releasing AHAP3 nanoparticles, MAP3 (containing only 
secondary amines) was employed as the aminosilane to create more biocompatible 
vehicles. As expected, the cytotoxicity of MAP3 controls against A2780 cells was 
significantly lower, whereas the NO release from NO donor-modified MAP3 silica remained 
cytotoxic against A2780 cells, with proliferation inhibited completely at 200 µg/mL (Fig. 2C). 
 
To preliminarily investigate the effect of nanoparticle size on the cell cytotoxicity of our NO-
releasing silica, we synthesized two sizes of 75 mol% MAP3 nanoparticles by varying the 
solvent system used during their preparation:  90 and 350 nm nanoparticles, designated as 
S- and L-MAP3, small and large MAP3 nanoparticles, respectively. We then treated 
untransformed immortalized human surface ovarian cells (HOSE), Ras-transformed HOSE, 
and a panel of ovarian carcinoma cell lines with control and NO-releasing S-MAP3 or L-
MAP3 (400 µg/mL) nanoparticles and determined loss of anchorage-dependent cell viability. 
The IC50 values for these analyses are summarized in Table 3.2 and representative data are 
shown in Fig. 3.  The NO-releasing S-MAP3 nanoparticles demonstrated comparable strong 
cytotoxicity against the entire panel of ovarian tumor cell lines as well as the paired 
immortalized and Ras-transformed HOSE cells (IC50 ~60-100 µg/mL). In contrast, the NO-
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releasing L-MAP3 nanoparticles while significantly cytotoxic towards the ovarian carcinoma 
cell lines and the Ras-transformed T29H and T80H cells, showed markedly decreased 
cytotoxicity toward the non-transformed T29 and T80 cells (2.3- to 3.4-fold; p-value ≤ 0.001) 
than the smaller diameter particles. This size-dependent tumor cell cytotoxicity may allow for 
the development of NO-based tumor-selective chemotherapies with lessened toxicity to 
normal cells. 
 
3.3.3 NO-Releasing Silica Nanoparticles Induce Apoptosis. To determine whether the 
NO-releasing MAP3 nanoparticles cause inhibition of growth by inducing apoptosis in 
ovarian cells, we examined the levels of cleaved caspase-3 and cleaved PARP (biochemical 
markers of apoptosis). Western blot analysis demonstrated induction of apoptosis through 
an increase in cleaved caspase-3 and cleaved PARP levels in T80 and T80 H-Ras cells 
after treatment with 400 µg/mL of NO-releasing L-MAP3 nanoparticles for 6 h (Fig. 4A). 
Cells were treated with 10 µM staurosporine for 1 h as a positive control for induction of 
apoptosis. Cleaved caspase-3 and PARP protein levels increased to a greater extent in the 
T80 H-Ras cells compared to the T80 cells. Pre-treatment of T80 H-Ras cells with the broad 
spectrum caspase inhibitor, z-VAD-FM, followed by NO-releasing L-MAP3 nanoparticle 
treatment prevented caspase-3 and PARP cleavage. In addition, T80 H-Ras cells either 
treated with staurosporine or 400 µg/mL of L-MAP3 NO-donor nanoparticles for 6 h stained 
positive for the apoptotic marker, annexin V Fluor 647, and the necrotic marker, PI (Fig. 4B). 
These data suggest that NO-releasing L-MAP3 nanoparticles induced apoptosis more so in 
transformed ovarian cells compared to immortalized normal ovarian cells through a 
caspase-dependent mechanism.   
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3.3.4 Anchorage-independent Growth is Inhibited in Transformed Ovarian Cells by 
Treatment with NO-releasing MAP3 Nanoparticles. We next investigated the ability of the 
NO-releasing nanoparticles to inhibit anchorage-independent growth by analyses of soft 
agar colony formation with cells treated with the small and large nanoparticles.  Single cell 
suspensions in agar were maintained in growth medium supplemented with either vehicle 
(i.e., media), control MAP3 nanoparticles, NO-releasing S-MAP3, or NO-releasing L-MAP3 
nanoparticles (200 µg/mL) and the appearance of proliferating colonies of cells was 
monitored for two weeks (Fig. 3). Both S- and L-MAP3 significantly reduced colony 
formation compared to control MAP3 nanoparticle treatment. These results further indicate 
the therapeutic potential of NO-releasing nanoparticles. 
 
3.3.5 Subcellular Localization of NO Donor Nanoparticles in Ovarian Cancer Cells. 
Previous studies have demonstrated uptake of nanoparticles such as silica and liposomes 
through the endocytic pathway.(Sun et al., 2008) To determine cellular localization of the 
NO-releasing silica nanoparticles, we modified the nanoparticles to fluoresce by co-
condensing FITC-modified APTMS, N-diazeniumdiolated MAP3, and TEOS.  Incorporation 
of FITC-modified APTMS did not have a significant effect on nanoparticle size or NO release 
(data not shown).   A2780 ovarian cancer cells were treated with FITC-labeled NO-releasing 
L-MAP3 (100 µg/mL) for either 1 or 24 h. Following treatment, the intracellular locations of 
mitochondria and lysosomes were determined by staining with either Mito-Traker or Lyso-
Tracker, respectively. Cells were then fixed and stained for early and late endosomes, ER or 
Golgi, and visualized by confocal microscopy. FITC-labeled NO-releasing L-MAP3 
demonstrated co-localization with the late endosomes and lysosomes after one and 24 h 
treatments (Figs. 6A and 6B). Furthermore, ovarian cancer cells treated for 1 h with NO-
releasing L-MAP3 (100 µg/mL) were also treated with DAF-2 DA, a fluorescent marker for 
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the presence of intracellular NO. As shown in Fig. 6C, no fluorescence was observed upon 
treatment with L-MAP3 (100 µg/mL), DAF-2 DA alone, or PYRRO/NO (100 µg/mL). 
Fluorescence did occur in cells treated with both L-MAP3 (100 µg/mL) and DAF-2 DA 
indicating the NO was present within the cell. A much larger concentration of PYRRO/NO 
(1000 µg/mL) was needed to observe similar fluorescence levels (NO concentration) in the 
cells. 
 
3.4 Discussion 
Although a variety of small molecule NO donors have been reported effective against 
different tumor types including pancreatic, colon, and ovarian cancers (Bratasz et al., 2006; 
Ouyang et al., 2008; Rosetti et al., 2006; Saavedra et al., 2006b), they have also suffered 
from highly toxic side effects of the drug byproduct and poor cellular permeability and 
retention. The development of novel delivery systems for NO donors that may overcome 
these limitations is of crucial importance to advance the feasibility of NO-based therapies. In 
this study, we employed NO-releasing silica scaffolds to assess the usefulness of 
nanoparticle-based NO delivery against ovarian cancer. When compared to control 
nanoparticles, the NO donor-modified nanoparticles demonstrated enhanced growth 
inhibition of ovarian tumor cells and preliminary size dependency support the anti-tumor 
efficacy of NO delivered from silica nanoparticles against ovarian cancer cells as well as the 
feasibility of materials based from these observations as a novel approach for cancer 
treatment. 
 
When compared to the small molecule NO donor PYRRO/NO, we found greater anti-tumor 
activity with the N-diazeniumdiolated-modified NO-releasing silica nanoparticles. While other 
small molecule NO donors exist, PYRRO/NO was chosen for study due to its NO release 
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mechanism allowing for a direct comparison between the NO-releasing silica nanoparticles 
and a previously reported small molecule NO donor. Without changing the structure of the 
NO donor functionality, we were able to prolong the NO using the silica nanoparticle.  
Although NO release may be further extended using more recent diazeniumdiolate 
chemistries (e.g., O2-arylated diazeniumdiolate), our goal was to keep this chemistry 
constant.  (N-diazeniumdiolates are characterized by a one-step proton-initiated dissociation 
mechanism, while O2-arylated diazeniumdiolates follow a two-step dissociation mechanism 
(i.e., S-glutathionylation and protonation) (Saavedra et al., 2006b). The dose of NO required 
to inhibit tumor cell growth was significantly decreased for the nanoparticles relative to NO 
derived from the small molecule. Due to an extremely short half-life (~3 s), the effective 
PYRRO/NO concentration is inherently larger because most of the NO is released prior to 
the small molecule being taken up by the target cell (Saavedra et al., 1997). Since the NO 
release from the nanocomposite scaffolds is prolonged (t1/2= 7 min), more NO is available 
for therapeutic use upon interaction between the nanoparticle and tumor cell. Presence of 
intracellular NO was confirmed using DAF-2 DA, a widely used NO-sensitive fluorescent 
probe (Kojima et al., 1998; Shao et al., 2003). Upon treatment with NO-releasing silica 
particles and DAF-2 DA, we observed intracellular DAF-2 fluorescence, confirming that our 
silica particles are capable of delivering significant levels of NO within the cell.  Due to the 
kinetics of NO release, it is likely that some of the payload is released prior to cellular uptake 
of the particles. However, the presence of DAF-2 fluorescence proves that the nanoparticles 
are successful in delivering NO to the cell. 
 
Based on our results, NO-releasing silica nanoparticles containing MAP3 are preferable 
over those composed of AHAP3.  Control MAP3 nanoparticles (i.e., non-diazeniumdiolated) 
demonstrated little to no cytotoxicity in our ovarian cell line panel, while control AHAP3 
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nanoparticles were slightly cytotoxic.  The increased cytotoxicity of AHAP3 over MAP3 
nanoparticles is attributed to the presence of the primary amine (Luo and Prestwich, 2002; 
Stasko et al., 2007). Furthermore, greater aminosilane concentrations were achievable for 
MAP3 particle systems, thus allowing higher NO payloads.  The primary amine of AHAP3 
interrupts particle formation at higher concentrations due to hydrogen bonding interactions. 
These results validate the MAP3 NO-releasing silica nanoparticles as a non-toxic carrier 
system for large NO payloads.  
 
Nanoparticle size is an important factor in determining the efficacy of a specific anti-cancer 
therapeutic approach. In the case of drug carriers, size may influence delivery volume, 
release characteristics, and accumulation site in the body such as tumor, liver, or bone 
marrow. Previous studies have shown size-dependent tumor-specific delivery of 
nanoparticles to the tumor microvasculator through the enhanced permeation and retention 
(EPR) effect (Kumar et al., 2005; Maeda et al., 2000). We found that increasing the size of 
the nanoparticle from d = 90 ± 10 nm to d = 350 ± 50 nm resulted in enhanced  preferential 
cytotoxicity for tumor versus nontumor ovarian cells. Although our initial studies were done 
in vitro, with evaluation of only two normal immortalized cell lines and their transformed 
isogenic counterparts, we believe that these observations are quite significant.  Future work 
will involve synthesizing a range of sizes and investigating not only efficiency of NO delivery 
but also how particle size affects uptake and distribution within cells.   
 
Many groups have determined that the mechanism of internalization and localization of 
nanoparticles was influenced greatly by size, surface properties, and cell line-dependence 
differences (Lu et al., 2007; Rejman et al., 2004; Slowing et al., 2006; Sun et al., 2008). 
Silica nanoparticles are known to be taken up via endocytosis and localize to endosomes 
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and lysosomes.  Thus, as expected, our analyses found that the NO-releasing silica 
nanoparticles entered the cytosol of the treated cells and localized to late endosomes and 
lysosomes. Our results show clearly that larger NO-releasing nanoparticles demonstrated 
enhanced destabilization of mitochondrial function and caspase-induced apoptosis in tumor 
versus non-tumor cells. The role of NO in the mitochondrial-mediation of apoptosis has been 
established (Boyd and Cadenas, 2002). The nitro-aspirin drug, NCX-4016, induced 
apoptosis by activation of caspase-3 and cleavage of the substrate PARP in ovarian cancer 
cells (Selvendiran et al., 2008). Similarly, the large NO-releasing nanoparticles induced cell 
death in T80 and more so in T80 H-Ras cells as shown by caspase-3 and PARP cleavage 
and staining positive for annexin V/PI. The smaller diameter particles exhibited greater 
cytotoxicity toward T80 cells than the larger particles.  Indeed, it has been shown that 
toxicity of amorphous silica is inversely related to particle size with diameters less than 100 
nm showing an increase in cytotoxicity (Oberdorster et al., 2005; Yu et al., 2009). This 
phenomenon is attributed to the fact that the surface area to volume ratio increases 
exponentially as particle size decreases. More atoms or molecules are expressed on the 
surface of smaller diameter particles per volume compared to larger particles therefore 
increasing the biological activity of the smaller nanoparticle. The enhanced cytotoxicity and 
caspase induced-apoptosis seen in T80 H-Ras cells after treatment with the large NO-
releasing nanoparticles may be attributed to the greater concentration of NO released by 
these scaffolds and/or NO targeting Ras-driven apoptotic pathways.  
 
While we have shown that NO-releasing silica nanoparticles are effective against ovarian 
tumor cells, modifications must be made to enhance the therapeutic potential due to the 
short half-life of NO release. Addition of an outer shell (i.e. TEOS) could temporarily protect 
the diazeniumdiolate functionalities and delay NO release. Alternatively, encapsulation of 
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the NO-releasing silica particles within a liposome would suspend NO release until 
obliteration of the liposome. Future studies will need to determine whether size selectivity is 
maintained in the much more complex in vivo environment, where pharmacodynamic and 
pharmacokinetic parameters will also influence nanoparticle-delivered NO anti-tumor activity 
and selectivity.  Furthermore, prior to in vivo testing, the surface of the particles will be 
modified with polyethylene glycol (PEG) to increase biocompatibility and blood circulation 
times (He et al., 2008; Ryan et al., 2008). 
 
3.5 Material and methods 
3.5.1 Cell lines, Drugs, and Antibodies.  
OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SKOV-3 ovarian cancer cells were 
provided by Dr. R. Camalier of Division of Cancer Treatment and Diagnosis Tumor 
Repository at NCI (Frederick, MD). A2780 ovarian cancer cell line was provided by Dr. T. 
Fojo of Cancer Therapeutics Branch at NCI (Bethesda, MD). The HeyA8 ovarian cancer cell 
line was provided by Dr. G. Mills at MD Anderson Cancer Center (Houston, TX). The 
immortalized, nontransformed human ovarian surface epithelial cell lines (T29 and T80) and 
matched H-Ras(12V)-transformed counterparts (T29 H-Ras and T80 H-Ras) were described 
previously.(Liu et al., 2004b)  All cell lines were maintained in either RPMI or DMEM 
medium supplemented with 10% fetal calf serum.  Z-VAD-FMK and staurosporine were 
obtained from Calbiochem (Gibbstown, NJ).  The caspase-3 and PARP antibodies were 
from Cell Signaling (Boston, MA), ERK1/2 antibody was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA), Mito- and Lyso-Tracker from Molecular Probes (Eugene, 
OR), Alexa-594 secondary from Invitrogen (Eugene, OR), EEA1 from BD Transduction 
(Mississauga, ON, Canada), calnexin from Affinity BioReagents (Golden, CO), and LAMP1 
from Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). 
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3.5.2 Chemicals.  
Tetraethoxysilane (TEOS), 3-methylaminopropyltrimethoxysilane (MAP3), pyrrolidine 
(PYRRO), and sodium methoxide were purchased from Fluka (Buchs, Switzerland). N-(6-
Aminohexyl)aminopropyltrimethoxysilane (AHAP3) and 3-aminopropyltrimethoxysilane 
(APTMS) were from Gelest (Tullytown, PA). Fluorescein isothiocyanate (FITC) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from Sigma (St. Louis, 
MO).  4,5-Diaminofluorescein diacetate (DAF-2 DA) was purchased from Calbiochem 
(Gibbstown, NJ). Methanol (MeOH), ethanol (EtOH), 2-propanol (PrOH), toluene, and 
ammonia solution (28 wt% in water) were from Fisher Scientific (Fair Lawn, NJ). Nitric oxide 
(NO), carbon dioxide (CO2) (5%), argon (Ar), and nitrogen (N2) gases were from AGA Gas 
(Maumee, OH) or National Welders Supply (Raleigh, NC). Other solvents and chemicals 
were analytical-reagent grade and were used as received. A Millipore Milli-Q UV Gradient 
A10 System (Bedford, MA) was used to purify distilled water to a final resistivity of 18.2 
MΩ·cm and a total organic content of ≤6 part per billion (ppb). 
 
3.5.3 Synthesis of Nitric Oxide Donor Pyrrolidine and Organically-Modified Silica 
Nanoparticles.  
Sodium 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (PYRRO/NO) was synthesized as 
previously reported.(Saavedra et al., 1997) Silica nanoparticles were prepared by the co-
condensation of tetraethyoxysilane (TEOS) with various ratios of an N-diazeniumdiolate-
modified aminosilane (i.e. AHAP3 or MAP3) as described in depth previously.34 To form the 
N-diazeniumdiolate NO donor moiety, aminoalkoxysilane solution was prepared by 
dissolution of an appropriate amount of aminoalkoxysilane (i.e., AHAP3 or MAP3) in a 
mixture of ethanol, methanol, and sodium methoxide (NaOMe) base and then reacted with 
NO (5 atm) for 3 d. Tetraalkoxysilane (i.e., TEOS) was then mixed with different ratios of the 
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N-diazeniumdiolate-modified aminoalkoxysilane (10–75 mol %, balance TEOS). Finally, the 
silane mixture was added to various solvent systems (e.g., 100% EtOH or 50/50% (v/v) 
EtOH/PrOH) in the presence of an ammonia catalyst (NH4OH) to form NO donor-modified 
silica nanoparticles via the sol-gel process.  Nitric oxide-loaded nanoparticles were stored in 
sealed containers at -20 °C to protect the diazeniumdiolate moiety from thermal and proton-
initiated decomposition.(Keefer et al., 1996) More recently, we have conducted experiments 
that indicate that storage in a closed container within an evacuated and sealed bag results 
in negligible NO loss for storage periods of several weeks at room temperature (data not 
shown).  Control nanoparticles were prepared by exposing N-diazeniumdiolate-modified 
nanoparticles to aqueous media until all NO was depleted. 
 
3.5.4 Characterization of N-diazeniumdiolate-Modified Silica Nanoparticles.  
NO release profiles of the N-diazeniumdiolate-modified silica nanoparticles were measured 
in deoxygenated phosphate buffered saline (PBS; 0.01 M, pH 7.4) at 37 °C using a Sievers 
NOA 280i chemiluminescence nitric oxide analyzer (Boulder, CO).32  Nanoparticle size was 
determined using atomic force microscopy (AFM) as previously described.(Shin et al., 2007) 
 
3.5.5 Growth Assays.  
The MTT assay was performed as previously described.(Stevens et al., 2008) Cells were 
seeded in six replicates at 1000 to 5000 cells per well in 96-well plates, incubated overnight, 
and exposed to serial dilutions of pyrrolidine, PYRRO/NO, AHAP3/NO, AHAP3, MAP3/NO, 
or MAP3 in PBS continuously for 72 h. The drug-containing medium was then removed and 
replaced with MTT solution (Sigma, St. Louis, MO), after which the cells were incubated for 
4 h at 37°C. After removal of the MTT, DMSO was added, and the absorbance was 
measured at 560 nm using a microplate reader. The results were expressed relative to the 
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absorbance of cells grown in the absence of drug. The IC50 values were calculated from 
triplicate independent experiments. Anchorage-independent growth soft agar colony 
formation assays were performed by seeding single cell suspensions in growth medium at 
10,000 cells/well supplemented with 0.4% bacto agar. Colonies formed within three weeks 
and were stained with MTT, then scanned on a Canon 9900F flat bed scanner (Canon, Lake 
Success, NY), and counted using Image J software (NIH, Bethesda, MD). 
 
3.5.6 Synthesis of Fluorescently-labeled NO-Releasing Silica Nanoparticles.  
NO-releasing silica nanoparticles were fluorescently labeled via a “one-pot” co-condensation 
of three silane precursors including FITC-modified APTMS, N-diazeniumdiolated MAP3, and 
TEOS. The synthesis of FITC-APTMS conjugates was adapted from a previous report.(Shin 
et al., 2007)  Briefly, fluorescently-modified APTMS was prepared by reacting 321 µmol 
APTMS with 7.704 µmol FITC for 24 h in darkness.  A 50 µL aliquot of the resulting product 
was then co-condensed with 3.24 mmol N-diazeniumdiolate-modified MAP3 and 1.39 mmol 
TEOS.  
 
3.5.7 Confocal Fluorescence Microscopy.  
Cells were plated on glass coverslips coated with 0.01% gelatin. Cells were fixed in 4% 
paraformaldehyde, permeabilized in 0.2% Triton X-100, blocked in 0.5% bovine serum 
albumin, and incubated in primary [GM130 (1:50 dilution), calnexin (1:500), EEA1 (1:250), or 
LAMP1 (1:500)] followed by secondary Alexa-594 antibodies. To stain for mitochondria and 
lysosomes, cells were incubated in growth medium containing either 100 nM Mito-Tracker or 
75 nM Lyso-Tracker for 30 min. To fluorescently monitor intracellular NO, cells were 
incubated in growth medium containing 100 µg/mL L-MAP3 NO-releasing nanoparticles 
alone (NO-MAP3 control) or 10 µM DAF-2 DA for 30 min.  Next, cells treated with 10 µM 
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DAF-2 DA were washed with PBS and incubated with medium alone (DAF-2 control), 100 
µg/mL L-MAP3 NO-releasing nanoparticles, 100 µg/mL PYRRO/NO, or 1000 µg/mL 
PYRRO/NO for 1 h. Apoptotic and necrotic cells were labeled using the annexin V Fluos 
staining kit (Roche, Penzberg, Germany). Cells were mounted on coverslips with FluorSave 
(Calbiochem; Gibbstown, NJ) and imaged with a Zeiss Laser Scanning Microscope (LSM 
510, Germany).  
 
3.5.8 Statistical Analysis.  
Data were evaluated by SigmaPlot (Systat Software; San Jose, CA), and represented as 
means ± SD. P ≤ 0.001 were considered significant for all analyses. 
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Figure 3.1 Real time NO release profiles A) and total NO release amounts B) for 
diazeniumdiolate-modified MAP3 silica nanoparticles at the indicated concentration 
(45, 55, 65, and 75 mol%; balance TEOS).  Inset plot A’) represents expansion of 
graph A from 0 to 1.0 h. 
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Figure 3.2 The MTT assay was performed to determine the cytotoxicity as a function of 
concentrations of: A) PYRRO/NO; B) 45 mol% AHAP3/NO, and C) 75 mol% MAP3/NO 
silica nanoparticles on the A2780 ovarian carcinoma cell line: ●, controls (i.e. 
pyrrolidine, non-diazeniumdiolated AHAP3 and MAP3 silica nanoparticles) and ○, NO 
releasing. The results were plotted as cell viability, which was measured by 
absorbance at a wavelength of 560 nm (y-axis) versus drug concentration (x-axis).  
Amount of NO released was calculated from the values listed in Table 3.1. 
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Figure 3.3 MAP3 NO-donor silica nanoparticles are cytotoxic to ovarian cells. The MTT 
assay was used to screen the cytotoxicity of control MAP3 silica nanoparticles alone, 
S-MAP3 NO-donor silica nanoparticles (d = 90 ± 10 nm), or L-MAP3 NO donor-
modified silica nanoparticles (d = 350 ± 50 nm) on a panel of ovarian cells.  The cell 
lines tested include ovarian cancer patient cell lines: HeyA8, OVCAR-3, OVCAR-4, 
OVCAR-5, OVCAR-8, A2780, and SKOV-3; the genetically-engineered isogenic cell 
lines: immortalized normal ovarian cells T29 and T80 and their H-Ras(G12V)-
transformed counterparts T29H and T80H.  IC50 values and standard deviations were 
calculated from three independent experiments and the p-values were calculated for 
comparing T29 and T80 small versus large MAP3 NO-donor nanoparticle IC50 values. 
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Figure 3.4 MAP3 NO-donor silica nanoparticles induce apoptosis in ovarian cells. A) 
T80 and T80H cells were untreated, treated with 10 µM staurosporine for 1 h, or 
treated with 400 µg/mL of NO-releasing L-MAP3 nanoparticles alone or in combination 
with 100 µM z-VAD-FMK for 6 h. Cell lysates were subjected to western blot analysis 
to probe for the apoptotic markers, cleaved-caspase 3 and cleaved-PARP, or loading 
control, total ERK1/2. B) T80H cells were untreated or treated with either 10 µM 
staurosporine for 1 h or 400 µg/mL of NO-releasing L-MAP3 nanoparticles for 6 h. 
Cells were then stained with annexin V Alexa Fluor 647 to label apoptotic and PI to 
label necrotic cells and then imaged under the Zeiss laser scanning confocal 
microscope. 
 
 
 
 103 
 
 
Figure 3.5 S- (d = 90 ± 10 nm) and L- (d = 350 ± 50 nm) NO donor-modified MAP3 
nanoparticles inhibited anchorage-independent growth of ovarian cells compared to 
control MAP3 silica. The soft agar assay was performed to evaluate the ability of NO 
donor-modified nanoparticles to inhibit the anchorage-independent growth of ovarian 
cancer cells (A2780 and HeyA8) and transformed ovarian cells [T29 H-Ras(G12V) and 
T80 H-Ras(G12V)]. Cells were suspended in soft agar supplemented with growth 
medium that contained either vehicle, control MAP3 (non-NO releasing), S-MAP3, or 
L-MAP3 NO-releasing nanoparticles. Colonies formed within three weeks: A) pictures 
were taken under the light microscope (50X) and B) colonies were stained with MTT 
and quantified using Image J software. 
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Figure 3.6 A2780 ovarian cancer cells were treated with 100 µg/mL L-MAP3 NO-
releasing nanoparticles for either 1 or 24 h. A) The mitochondria or lysosomes were 
labeled through incubation of the cells with media containing either Mito-Tracker or 
Lyso-Tracker. Cells were fixed and stained for the remaining cellular compartments 
with GM130 (Golgi), calnexin (ER), EEA1 (early endosomes), or LAMP1 (late 
endosomes) primary antibodies. Cells were then stained with a secondary Alexa-594 
antibody and imaged under the Zeiss laser scanning confocal microscope. B) The 
enlarged single cell view of A2780 cells treated with MAP3 NO-releasing nanoparticles 
for 1 h stained for late endosomes and lysosomes indicates co-localization. C) A2780 
cells were treated with 100 µg/mL L-MAP3 NO-releasing nanoparticles alone (NO-
MAP3 control) or 10 µM DAF-2 DA for 30 min.  Next, cells treated with 10 µM DAF-2 
DA were washed with PBS and incubated with medium alone (DAF-2 control), 100 
µg/mL L-MAP3 NO-releasing nanoparticles, 100 µg/mL PYRRO/NO, or 1000 µg/mL 
PYRRO/NO for 1 h. Cells were imaged under the Zeiss laser scanning confocal 
microscope. 
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Table 3.1 NO release properties of silica nanoparticles. 
Aminoalkoxysilane 
(type)       (mol%) 
Diameter 
(nm) 
t[NO]a 
(µmol/mg) 
AHAP3 10 161 ± 23 0.56 
 25 142 ± 15 1.59 
 35 128 ± 11 2.58 
 45 136 ± 15 3.77 
MAP3 45 155 ± 25 1.59 
 55 140 ± 20 2.90 
 65 120 ± 15 4.30 
 70   97 ± 15 6.21 
 75   90 ± 10 7.35 
  75b 350 ± 50 12.52 
at[NO], total amount of NO released. bEtOH/PrOH (50:50 
v/v%) solvent system used during sol–gel polymerization.  
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Table 3.2 Effect of NO-releasing silica 
nanoparticle size on IC50 for inhibition of 
cellular viability.a 
IC50, µg/mL  Cell lineb 
S-MAP3c L-MAP3d 
HeyA8 100 ± 5.8 85 ± 5.5 
OVCAR-3 75 ± 4.3 60 ± 5.3 
OVCAR-4 87 ± 6.7 92 ± 8.8 
OVCAR-5 75 ± 3.2 65 ± 5.4 
OVCAR-8 90 ± 4.2 90 ± 5.8 
A2780 63 ± 5.2 30 ± 3.7 
SKOV-3 80 ± 8.9 63 ± 7.1 
T29e 62 ± 8.2 150 ± 17 
T80e 90 ± 8.6 220 ± 24 
T29Hf 90 ± 7.7 62 ± 7.3 
T80Hf 64 ± 5.1 61 ± 6.2 
aValues were determined by the MTT assay. 
bHuman ovarian cancer cell lines, except 
where noted. cDiameter of S-MAP3 = 90 ± 10 
nm; and ddiameter of L-MAP3 = 350 ± 50 nm. 
eImmortalized normal human ovarian surface 
epithelial cell lines. fTransformed with 
constitutively activated mutant H-Ras(G12V).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
 
4.1 Summary 
My research on RhoGDI2 demonstrates a metastasis suppressor function in ovarian 
carcinoma. As discussed previously, RhoGDI2 functions as either a metastasis suppressor 
or oncoprotein in different cancer types, such as bladder and breast cancer, respectively. A 
previous proteomic analysis of three invasive ovarian cancers and two noninvasive, low 
malignant potential ovarian tumors found that RhoGDI protein was overexpressed in more 
invasive tumors (Jones et al., 2002).  However, there are three human isoforms of RhoGDI 
(RhoGDI1, RhoGDI2 and RhoGDI3) and the overexpressed isoform was not identified in this 
study.  Another study demonstrated RhoGDI2 as a biomarker for ovarian cancer and its 
expression was highest in early stage ovarian cancers (Zhen et al.). My study provided the 
first assessment of a functional role for RhoGDI2 overexpression in ovarian cancer cell 
growth. 
 
I have shown that RhoGDI2 protein expression levels are differentially expressed in a panel 
of ovarian cancer cell lines. Knockdown of RhoGDI2 in ovarian cancer cells resulted in the 
increase in invasion in Matrigel chamber assay and tail-vein lung metastatic ability of 
ovarian cancer cells. I also demonstrated that RhoGDI2 associates with Rac1 in ovarian 
cancer cells, but not with other Rho GTPases tested (Cdc42, RhoA, and RhoC). One major 
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limitation of my study was that it focused only on the classical Rho GTPases.  It remains 
logical and likely that RhoGDI2 will interact with other members of the Rho GTPase family, 
and consequently, altered RhoGDI2 expression will impact their activities as well as those of 
Rac1.  It would be interesting to examine which of the non-classical Rho GTPase family 
members bind to and are regulated by RhoGDI2. I have shown here that knockdown of 
RhoGDI2 results in decreased Rac1 activity. It would be interesting to determine if Rac1 
activity is the basis for RhoGDI2-regulated oncogenesis. Finally, it will be interesting to test 
by immunohistochemistry of ovarian tumor tissue microarrays, if RhoGDI2 is a prognostic or 
diagnostic biomarker for ovarian cancer patients. In this chapter, I discuss future research 
directions to further enhance our understanding the role of RhoGDI2 in ovarian 
oncogenesis. 
 
In our studies, we have demonstrated the first application of nanoparticle-derived NO as a 
drug for inhibiting ovarian carcinoma tumor growth. Previously developed small molecule 
NO donor drugs have demonstrated anticancer activity, although they exhibited toxic side 
effects due to the byproduct of the drug (Keiko et al., 2006). The targeting capabilities 
available with nanoparticle-based drug delivery provide an attractive approach to overcome 
these limitations with improved site-specific delivery to the tumor due to their non-toxic 
nature and ability to form structures of tunable size and surface functionalities (Byrne et al., 
2008; Cho et al., 2008). Our studies provide a critical first step in the validation of this 
approach for anti-cancer treatment. 
 
I have shown that novel MAP3 NO-releasing nanoparticles inhibit in vitro growth of ovarian 
tumor cells when compared to MAP3 nanoparticles alone and the small molecule NO donor 
drug, PYRRO/NO. Also, NO-releasing nanoparticles inhibited anchorage-independent and -
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dependent growth of ovarian cancer cells. Interestingly, I observed a nanoparticle size 
dependency of efficacy against normal versus transformed ovarian cells. It will be interesting 
to test whether size selectivity is maintained in the much more complex in vivo environment, 
where pharmacodynamic and pharmacokinetic parameters will also influence nanoparticle-
delivered NO antitumor activity and selectivity. In addition, the NO-releasing nanoparticles 
entered the cytosol of the cell, released NO, and localized to late endosomes and 
lysosomes. Finally, the tumor in vivo is comprised of stromal tissue and variable tumor 
vasculature, factors that can greatly influence the ability of nanoparticles to reach the tumor.  
In this chapter, I discuss future research directions to determine if the NO-releasing silica 
nanoparticles inhibit ovarian cancer tumor growth in xenograft models and genetically 
engineered mouse models (GEMMS) of ovarian cancer.  
 
4.2 Future Direction I: Is Rac1 activity the basis for RhoGDI2-regulated oncogenesis? 
It has been demonstrated that RhoGDI2 modulates cancer cell metastasis by regulating 
Rac1 activity. Rac1 functions as a positive mediator in bladder cancer, but conversely, a 
negative regulator of cancer metastasis in breast and gastric cancer (Cho et al., 2009; 
Theodorescu et al., 2004; Zhang et al., 2009). This may be explained by the sometimes 
opposing roles Rac GTPases may play in regulating cell growth, migration, invasion, and 
survival, resulting in either stimulatory or inhibitory signals depending on microenvironment, 
genetic background, and cancer type.  
 
My studies have shown that RhoGDI2 is a positive regulator of Rac1 in that it binds Rac1, 
increases Rac1 activity, and increases phosphorylation of elements of the downstream 
pathway of Rac1, pMKK3/6/p38/JNK, in HeyA8 ovarian carcinoma cells. This result is 
surprising in that the association of RhoGDI2 with the switch II sequences of Rac1 may be 
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expected to prevent effective GEF interaction.  More studies are needed to determine if 
Rac1 activity is the basis for RhoGDI2-regulated oncogenesis. First, we will knockdown 
Rac1 in HeyA8 cells and determine if this mimics the phenotypic changes demonstrated in 
cells with RhoGDI2 knockdown such as changes in anchorage-independent growth, Matrigel 
invasion, and downstream signaling pathways (e.g., phospho-MKK3/6/p38/JNK). 
Alternatively, will expression of constitutively activated Rac1 prevent RhoGDI2 suppression-
mediated consequences? These key experiments will help us determine if activation of 
Rac1 by RhoGDI2 is important for the role of RhoGDI in ovarian cancer oncogenesis. 
 
Understanding how RhoGDI2 induces Rac1 activation is also another important question we 
would like to address in the future. RhoGDI2 may shuttle Rac1 to a new localization where it 
can interact with GEF proteins and become activated. RhoGDI2 is known to associate with 
the RacGEF, Vav1, during T-cell activation and enhances the effects of Vav1 (Groysman et 
al., 2000). Another study demonstrated that RhoGDI2 interacts with Vav1 for Cox-2 
expression through NFAT activation in breast cancer cells (Schunke et al., 2007).  Another 
possibility is that RhoGDI2 may inhibit GAP stimulation of Rac. It has been demonstrated 
that RhoGDI1 can form complexes with Rac proteins in their GTP/GDP bound states and 
can block GAP activity of BCR toward Rac (Hancock and Hall, 1993). RhoGDI2 was shown 
to bind BCR in COS-1 cells and block its GAP activity. The biological consequence of these 
findings has yet to be determined (Kweon et al., 2008). It would be interesting to determine if 
RhoGDI2 is transporting Rac1 to a specific subcellular localization and acting as a scaffold 
for interaction with GEFs and GAPs.  To test this, we will perform RhoGDI2 pulldown assays 
and determine if GEFs or GAPs bind RhoGDI2 in HeyA8 cells. Next, to determine if these 
GEFs or GAPs influence RhoGDI2-regulated oncogenesis, we will knockdown the GEFs or 
GAPs in HeyA8 cells and determine if this mimics the phenotypic changes demonstrated in 
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cells with RhoGDI2 knockdown such as changes in anchorage-independent growth, Matrigel 
invasion, and phospho-MKK3/6/p38/JNK components.  
 
4.3 Future Direction II: RhoGDI2 binds and alters the subcellular localization of which 
Rho GTPase family members? One important goal of my studies will be to provide a more 
thorough identification of the Rho GTPases that may be regulated by RhoGDI2.  For 
example, most studies have focused on the ability of RhoGDI2 to regulate RhoA and Rac1 
function, and not the related RhoB and RhoC isoforms (Dovas and Couchman, 2005).  
Despite the strong sequence and biochemical similarities seen with RhoA, RhoB and RhoC, 
significant biological differences and roles in oncogenesis have been seen (Horiuchi et al., 
2003; Michaelson et al., 2001; Michiels et al., 1995; Yoshioka et al., 1999). There is 
evidence that RhoB, localized to endosomes, may function more as a tumor suppressor 
rather than an oncogene (Liu et al., 2001).  RhoC, rather than RhoA, appears to be more 
important for tumor cell invasion (Horiuchi et al., 2003).  Other Rho GTPases, such as RhoH 
or RhoG, have very distinct functions (Gu et al., 2005; Vincent et al., 1992).  It will be 
important to know if the deregulated function of RhoGDI2 impacts on the function of these 
less-studied Rho GTPases. 
  
To test the hypothesis that RhoGDI2 regulates the function of Rho GTPases beyond the 
classical Rho GTPases, we will perform co-transfection experiments with 20 GFP-tagged 
Rho GTPases and RhoGDI2 constructs (Michaelson and Philips, 2006).  We will transiently 
transfect, using a lipofectamine based transfection procedure, NIH3T3 cells with pEGFP 
expression constructs containing each of the 20 Rho GTPases, either alone or together with 
an HA-tagged expression construct containing RhoGDI2.  Empty vector pEGFP will serve as 
the negative control.  After 24 h, cells will be fixed, permeabilized, and stained using an anti-
RhoGDI2 antibody and a secondary anti-goat antibody conjugated to Alexa Fluor-594 
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fluorphore.  Cells will be visualized using confocal microscopy.  RhoGDI2 primary and 
secondary anti-goat antibodies stained individually in NIH3T3 cells will serve as background 
fluorescent controls.  The different Rho GTPases exhibit distinct subcellular localizations, in 
association with the plasma membrane, Golgi and endoplasmic reticulum membranes, and 
endosomes (Michaelson et al., 2001).  Inhibition of prenylation disrupts Rho GTPase 
localization, resulting in nuclear and cytosolic accumulation of the GFP-tagged protein 
(Michaelson et al., 2001).  If we find that co-expression of RhoGDI2 causes a cytosolic 
relocalization, this would support the ability of RhoGDI2 to regulate the localization of that 
specific Rho GTPases.  
 
In addition cell lysates will be subjected to immunoprecipitation experiments to determine if 
RhoGDI2 is in a complex with GFP-tagged Rho GTPases.  The immunoprecipitation 
procedure entails incubating cell lysates first with GFP antibody followed by protein G-
Sepharose beads.  Next, the GFP immunoprecipitated cell lysates will be subjected to 
Western blot analysis probing with an anti-RhoGDI2 antibody.  Cell lysates incubated with 
protein G-Sepharose beads alone will serve as negative background controls. 
 
To assess whether the membrane or cytosol localizations of Rho GTPases are altered in 
RhoGDI2 overexpressing ovarian tumor cells, we will use the aforementioned stable 
RhoGDI2 knockdown and control HeyA8 ovarian cancer cell lines.  We will perform 
subcellular fractionation analysis to quantitate the extent of Rho GTPase membrane 
association. High-speed centrifugation of lysates will be used to isolate soluble (S100) 
cytosolic and membrane (P100) particulate fraction of cells.  Next, we will perform western 
blotting of S100 and P100 fractions, probing with anti-RhoA/C, anti-Rac1, and anti-Cdc42 
antibodies.   
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Next we will determine if RhoGDI2 regulates the function of the specific Rho GTPases 
discovered to bind RhoGDI2. Following knockdown of each particular Rho GTPase, 
anchorage-independent growth and Matrigel invasion assays will be performed. This will 
provide more insight into how the interaction of RhoGDI2 with Rho GTPases affects the 
transformed growth and invasion of cancer cells. 
 
I expect to find that RhoGDI2 will bind and alter the subcellular location of additional 
members of the Rho GTPase family. Since preliminary data suggest the knockdown of 
RhoGDI2 increases invasion, then I would predict that RhoGDI2 would bind to and 
relocalize Rho GTPases known to be important for invasion, such as RhoC. If RhoGDI2 
binds and localizes Rho GTPases to the cytosol in ovarian cancer cells, then we anticipate 
that RhoGDI2 knockdown in cells will show increased levels of Rho GTPases in the P100 
fractions, whereas, the S100 fractions will show increased levels of Rho GTPases for the 
RhoGDI2-overexpressing cells. In addition, if knockdown of the Rho GTPases discovered to 
bind RhoGDI2 alters anchorage-independent growth or Matrigel invasion, this would 
potentially provide more insight into the function of Rho GTPases in RhoGDI2-mediated 
oncogenesis.  
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Figure 4.1 Proposed model for how RhoGDI2 alters the metastatic state of ovarian 
carcinoma. A) For non-invasive ovarian cancers, RhoGDI2 binds a subset of Rho GTPases 
and shuttles them from the membrane to cytosol. Once membrane bound and active, Rho 
GTPases signal to multiple downstream signaling pathways important for cell movement.  
These pathways include p160ROCK which signals to LIMK-cofilin resulting in F-actin 
stabilization. In addition, p160ROCK inhibits MLC phosphorylation that inhibits MLC 
phosphorylation resulting in actin:myosin crosslinking. Rho also activates mDia which drives 
actin polymerization and the serum response factor which promotes the expression of c-fos 
and other genes whose products are associated with cell proliferation. 
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Figure 4.1 Proposed model for how RhoGDI2 alters the metastatis-state of ovarian 
carcinoma. B) For invasive ovarian cancers, mutational activation and/or aberrant 
expression of receptor tyrosine kinases (RTKs), kinases such as Src or Pak1, and 
enhanced activity of Rho GTPases leads to enhanced invasion and tumor growth driving a 
more aggressive phenotype. RhoGDI2 may bind and inhibit activation of Rho GTPases 
important for tumor suppression such as RhoB or may cycle Rho GTPases, Rac1 or  
unknown Rho GTPases (RhoX) to new subcellular localizations where they are able to 
interact with GEFs and become active, driving downstream pathways important for 
metastasis.  
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4.4 Future Direction III: Is RhoGDI2 a prognostic or diagnostic marker for ovarian 
carcinoma patients? RhoGDI2 has been found to be overexpressed in several types of 
cancers, including ovarian (Cho et al., 2009; Jones et al., 2002; Zhang and Zhang, 2006; 
Zhen et al.). One study demonstrated RhoGDI2 overexpression in ovarian serous carcinoma 
as compared with benign serous adenoma in a large-scale complementary DNA microarray 
study (Singer et al., 2002). A second study identified RhoGDI (isoform unknown) 
overexpressed in more invasive ovarian cancer patient tissues (Jones et al., 2002). It has 
also been reported that RhoGDI2 is overexpressed in ovarian cancers that are paclitaxel-
responsive as compared to nonresponsive to this drug (Goto et al., 2006). More recently, it 
was reported RhoGDI2 levels in serum as a diagnostic marker for ovarian cancer patients 
compared to benign disease and healthy individuals, especially for identification of early 
stage ovarian cancer (Zhen et al.). In this study, immunohistochemistry confirmed the 
expression of RhoGDI2 protein in cancerous but not benign epithelial cells. Currently, the 
specificity of RhoGDI2 as a prognostic or diagnostic marker for ovarian carcinoma patients 
needs to be validated in a larger patient data set.  
 
In my ongoing studies, we are currently determining if RhoGD2 protein expression may be a 
diagnostic or prognostic biomarker for ovarian cancer patients by using 
immunohistochemistry of ovarian tumor tissue microarrays (TMAs) from MD Anderson 
containing over 400 patient tissues with known clinical history. We have validated the 
RhoGDI2 antibody for immunohistochemisty and preliminary data demonstrate that 
RhoGDI2 is differentially expressed between different subtypes of ovarian cancer and cysts 
(Figure 4.2). It will be interesting to determine if RhoGDI2 is a prognostic marker for ovarian 
cancer and is expressed highly in early stage ovarian cancer, as previous described. If we 
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find that RhoGDI2 is lost in more invasive advanced stage ovarian cancers, then this would 
strengthen the hypothesis that RhoGDI2 is a metastasis suppressor in ovarian carcinoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
 
 
 
 
 
 
 
Figure 4.2 Variable RhoGDI2 expression in patient-derived ovarian tumor tissue. 
A) Negative and positive control paraffin-embedded ovarian cancer cell lines that 
express low levels of RhoGDI2 (A2780) and high levels of RhoGDI2 (HeyA8). B) 
The paraffin-embedded blocks of ovarian tissue (normal tissue), early stage 
ovarian cancer (stages I and II) and advanced stage ovarian cancer (stages III 
and IV) were stained with a goat polyclonal antibody against RhoGDI2 (brown) 
and counterstained with hematoxylin (blue).  
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4.5 Future Direction IV: Do NO-releasing MAP3 silica nanoparticles inhibit ovarian 
carcinoma tumor growth in vivo? There is already significant evidence of previously 
developed NO donor drug inhibition of tumor growth in xenograft mouse models. A recent 
study found that PABA/NO showed activity against mouse human tumor cell line xenografts 
of the A2780 ovarian carcinoma cell line that was similar to that of cisplatin (Findlay et al., 
2004). Another study found that NO sensitized the A2780 and AD10 ovarian carcinoma cell 
lines to Fas ligand-mediated apoptosis (Garban and Bonavida, 1999). It would be interesting 
to determine if the MAP3 NO-donor nanoparticles demonstrate anti-tumor activity in ovarian 
cancer xenograft models. 
 
We have determined that NO releasing silica nanoparticle treatment causes the inhibition of 
ovarian carcinoma cell line anchorage-dependent and anchorage-independent growth in 
vitro.  To determine the ability of NO releasing silica nanoparticles to ovarian tumor cell line 
tumorigenic growth in nude mice, it is crucial to test the pharmacodynamic properties of 
silica nanoparticles in nude mice.  Second, these analyses will establish the dosing and 
delivery protocol that will be used to determine the anti-tumor activity of NO releasing silica 
nanoparticles in vivo. 
 
Ultimately, to achieve our long-term goal of engineering novel targeted NO nanoparticles 
that selectively kill tumor cells in vivo, we plan initially to evaluate the biological distribution 
and potential normal tissue toxicity of silica nanoparticles in mice. The nanoparticles will be 
loaded with a common contrasting agent, iron-oxide, that will allow us noninvasively to 
follow the particles in the body through magnetic resonance imaging (MRI) (Figure 4.3).  
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Figure 4.3 Synthesis of diazeniumdiolate-modified magnetic silica (core/shell) 
nanospheres. A) To synthesize magnetic core/silica shell nanoparticles, NO donor 
nanoparticles will be dispersed under ultrasonic agitation in ethanol and ammonia and 
then 10 mol% of MAP3 (balance TEOS) will then be deposited on the surface of the core 
particles via the one-pot synthesis. The Fe3O4/aminated silica core/shell nanospheres will 
then be charged with NO to form diazeniumdiolate-modified magnetic nanoparticles. B) 
The reaction of 4-nitrophenyl chloroformate and poly(ethylene glycol) monomethylether 
(M-PEG) in the presence of an amine catalyst yields M-PEG 4-nitrophenyl carbonate 
(Kojima et al., 2000). The PEG-coated MAP3 silica nanoparticle will display increased 
water solubility and clearance during biodistribution studies. 
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Magnetic nanoparticles have been studied extensively for many applications including 
cancer diagnosis due to enhancement of MR signal. In addition, the particles will be 
composed of the polymeric substrate, PEG. PEG modifications have been shown to 
increase blood circulation time through preventing protein binding and reticuloendothelial 
system (RES) uptake via steric repulsion mechanism. 
 
First, dose-seeking experiments will be performed based on previous studies that examined 
biodistribution of MNP silica nanoparticles. Nude mice will be injected (i.v. tail-vein 
injections) with 1) silica nanoparticles alone, 2) PEG-coated silica nanoparticles, 3) iron-
oxide silica nanoparticles, or 4) PEG-coated iron-oxide silica nanoparticles. Weight loss and 
other signs of stress and toxicity will be examined and necropsies will be performed to 
identify additional toxicities. To evaluate pharmacokinetics and tissue biodistribution of 
nanoparticles at various time intervals, the mice will be sacrificed and subjected to MRI. 
Nanoparticle biodistribution in the blood, liver, spleen, kidney, lung, heart, intestine, bone, 
bone marrow, urine, and feces will be quantified by standard protocols and analyses (He et 
al., 2008). Pharmacokinetic variables such as half-life, clearance from plasma, volume of 
distribution, area-under-the-curve as a function of time, will be determined as previously 
described in similar nanoparticle delivery studies (Kaul and Amiji, 2004; Kommareddy and 
Amiji, 2007).  Finally, since advanced ovarian tumors are characterized by intraperitoneal 
(i.p.) progression, we will also evaluate nanoparticle clearance from peritoneal fluid after i.p. 
inoculation.  
 
Once the above studies establish nanoparticle pharmacokinetic properties, the dosing and 
scheduling will then be determined for evaluation of NO nanoparticle ability to inhibit ovarian 
tumor growth in xenograft models and GEMMS of ovarian cancer. The standard anticancer 
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drug development pipeline uses xenograft models as the primary in vivo models for 
investigating drug candidate efficacy and mechanism of action (Singh and Johnson, 2006). 
However, the prognostic usefulness of xenograft models for human clinical trials has been 
limited due to the lack of a host immune system, absence of neoangiogenesis, and 
accumulation of numerous undefined genetic aberrations because of extended propagation 
(Orsulic et al., 2002). Recently, GEMMS for epithelial ovarian cancer have been developed 
and have the advantage of inducing malignant transformation of intact ovarian surface 
epithelial cells in their natural environment in adult mice with genetically predefined steps 
(i.e., Cre-loxP models with K-RasG12D/+/PTENloxP/loxP) and serve as a valuable models of 
metastatic ovarian cancer for testing novel therapies (Connolly et al., 2003). After tumor 
formation in the xenograft and GEMMS, mice will be treated with either NO nanoparticles or 
empty silica nanoparticles. Mice will then be sacrificed and the tumor size will be measured.  
 
Additionally, the magnetic composition of the nanoparticles will allow magnetic heating 
coupled with NO release, which may provide a novel synergistic therapy for the treatment of 
tumors. “Hyperthermia” has been studied extensively as a promising cancer therapy since 
tumor cells are more susceptible to death at high temperatures (>42°C) relative to normal 
cells (Jordan et al., 1999a; Wust et al., 2002). These hyperthermic treatments of tumor cells 
are combined readily with magnetic particle systems because the magnetic particles are 
able to absorb energy and heat the surrounding tissue by hysteresis loss (Gupta and Gupta, 
2005; Jordan et al., 1999a; Wust et al., 2002). Therefore, in addition to the therapeutic 
efficacy of NO released from the shell structure, magnetic nanoparticles may be useful for 
destroying tumor cells via a hyperthermic process.  
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Interestingly, normal ovarian epithelial cells display much lower levels of folate receptor (FR) 
expression making FR a valuable therapeutic target for ovarian cancer (Parker et al., 
2005a). The FR is frequently overexpressed in many cancer types, with the highest 
frequency being ovarian cancers (>90%) (Corona et al., 1998). One study found normal 
human lung tissue displayed high expression levels, although considering that folate-drug 
conjugates do not accumulate in the lungs of patients, this is not considered to be of clinical 
concern (Parker et al., 2005b). FR is a glycosylphosphatidylinositol-anchored membrane 
protein that binds folic acid and mediates the cellular uptake of vitamin and drug conjugates 
via endocytosis (Muller et al., 2006). Attaching folic acid to the NO-donor nanoparticles may 
allow selective delivery of the nanoparticles in ovarian cancer and non-neoplastic ovarian 
HOSE cells. We will evaluate the selectivity of the folate acid-tagged nanoparticles for 
targeting and decreasing cell viability of ovarian cancer cells expressing FR. Western 
blotting will be performed with an FR specific antibody to determine FR protein expression 
levels in ovarian cancer and HOSE cell lines. We will compare the cytotoxicity profiles 
against the FR protein expression levels of the cell lines. This will allow us to determine if 
higher ER expressing cell lines are more cytotoxic to folic acid nanoparticles. Next, we will 
perform overexpression and knockdown experiments to determine if FR is the molecular 
target of the folic acid nanoparticles. Ultimately, it will be interesting to determine if the 
MAP3 NO-donor nanoparticles demonstrate anti-tumor activity in vivo and if additional 
modifications (e.g., attaching FR) will further enhance the tumor selectivity of nanoparticle-
delivered therapies.  
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